export const json = {
    "resourceType": "Bundle",
    "id": "aedf3c49-788e-4d0e-acb0-04844f962c73",
    "meta": {
        "lastUpdated": "2025-04-16T16:28:45.282773+00:00"
    },
    "type": "searchset",
    "link": [
        {
            "relation": "self",
            "url": "http://prod-iris-epi-fhir-r5-001-app.azurewebsites.net/Bundle?_count=1000"
        }
    ],
    "entry": [
        {
            "fullUrl": "http://prod-iris-epi-fhir-r5-001-app.azurewebsites.net/Bundle/032f3906-1733-45ad-8fab-325d51fac4cf",
            "resource": {
                "resourceType": "Bundle",
                "id": "032f3906-1733-45ad-8fab-325d51fac4cf",
                "meta": {
                    "versionId": "1",
                    "lastUpdated": "2024-02-13T11:13:52.263+00:00"
                },
                "identifier": {
                    "system": "http://ema.europa.eu/fhir",
                    "value": "482d755b-0932-ee11-bdf4-000d3aaa0146"
                },
                "type": "document",
                "timestamp": "2023-08-31T12:09:58.065876+00:00",
                "entry": [
                    {
                        "fullUrl": "http://ema.europa.eu/fhir",
                        "resource": {
                            "resourceType": "Composition",
                            "language": "en",
                            "status": "final",
                            "type": {
                                "coding": [
                                    {
                                        "system": "https://spor.ema.europa.eu/v1/lists/100000155531/terms/",
                                        "code": "100000155532",
                                        "display": "Summary of Product Characteristics"
                                    }
                                ]
                            },
                            "date": "2023-08-31",
                            "author": [
                                {
                                    "identifier": {
                                        "system": "http://www.test.com",
                                        "value": "systemuser"
                                    }
                                }
                            ],
                            "title": "Imatinib Teva",
                            "section": [
                                {
                                    "id": "492d755b-0932-ee11-bdf4-000d3aaa0146",
                                    "title": "SUMMARY OF PRODUCT CHARACTERISTICS",
                                    "code": {
                                        "coding": [
                                            {
                                                "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                "code": "100000155532",
                                                "display": "SUMMARY OF PRODUCT CHARACTERISTICS"
                                            }
                                        ]
                                    },
                                    "text": {
                                        "status": "generated"
                                    },
                                    "section": [
                                        {
                                            "id": "4a2d755b-0932-ee11-bdf4-000d3aaa0146",
                                            "title": "1. NAME OF THE MEDICINAL PRODUCT",
                                            "code": {
                                                "coding": [
                                                    {
                                                        "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                        "code": "200000029792",
                                                        "display": "1. NAME OF THE MEDICINAL PRODUCT"
                                                    }
                                                ]
                                            },
                                            "text": {
                                                "status": "generated",
                                                "div": "<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Imatinib Teva 100&#160;mg hard capsules</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Imatinib Teva 400&#160;mg hard capsules</p>"
                                            }
                                        },
                                        {
                                            "id": "4b2d755b-0932-ee11-bdf4-000d3aaa0146",
                                            "title": "2. QUALITATIVE AND QUANTITATIVE COMPOSITION",
                                            "code": {
                                                "coding": [
                                                    {
                                                        "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                        "code": "200000029793",
                                                        "display": "2. QUALITATIVE AND QUANTITATIVE COMPOSITION"
                                                    }
                                                ]
                                            },
                                            "text": {
                                                "status": "generated",
                                                "div": "<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Imatinib Teva 100&#160;mg hard capsules</u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Each hard capsule contains 100&#160;mg of imatinib (as mesilate).</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; text-align: justify; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Imatinib Teva 400&#160;mg hard capsules</u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Each hard capsule contains 400&#160;mg of imatinib (as mesilate).</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">For the full list of excipients, see section 6.1.</p>"
                                            }
                                        },
                                        {
                                            "id": "532d755b-0932-ee11-bdf4-000d3aaa0146",
                                            "title": "3. PHARMACEUTICAL FORM",
                                            "code": {
                                                "coding": [
                                                    {
                                                        "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                        "code": "200000029797",
                                                        "display": "3. PHARMACEUTICAL FORM"
                                                    }
                                                ]
                                            },
                                            "text": {
                                                "status": "generated",
                                                "div": "<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Hard capsule.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Imatinib Teva 100&#160;mg hard capsules</u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Non transparent orange capsules with black marking 7629 on capsule body and black marking TEVA on capsule cap. The content of the capsule is white to light yellow granulated powder.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">The length of the capsule is from 19.1 mm to 19.7 mm and the width is 6.91 mm.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Imatinib Teva 400&#160;mg hard capsules</u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Non transparent orange capsules with black marking 7630 on capsule body and black marking TEVA on capsule cap. The content of the capsule is white to light yellow granulated powder.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">The length of the capsule is from 23.0 mm to 23.6 mm and the width is 8.53 mm.</p>"
                                            }
                                        },
                                        {
                                            "id": "572d755b-0932-ee11-bdf4-000d3aaa0146",
                                            "title": "4. CLINICAL PARTICULARS",
                                            "code": {
                                                "coding": [
                                                    {
                                                        "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                        "code": "200000029798",
                                                        "display": "4. CLINICAL PARTICULARS"
                                                    }
                                                ]
                                            },
                                            "text": {
                                                "status": "generated"
                                            },
                                            "section": [
                                                {
                                                    "id": "582d755b-0932-ee11-bdf4-000d3aaa0146",
                                                    "title": "4.1 Therapeutic indications",
                                                    "code": {
                                                        "coding": [
                                                            {
                                                                "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                                "code": "200000029799",
                                                                "display": "4.1 Therapeutic indications"
                                                            }
                                                        ]
                                                    },
                                                    "text": {
                                                        "status": "generated",
                                                        "div": "<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Imatinib Teva is indicated for the treatment of</p>\n<ul style=\"margin-bottom: 0cm; margin-top: 0px;\">\n<li style=\"line-height: normal; margin: 0cm 0cm 0.0001pt 0px; font-size: 11pt; font-family: 'Times New Roman', serif;\">adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr‑abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.</li>\n<li style=\"line-height: normal; margin: 0cm 0cm 0.0001pt 0px; font-size: 11pt; font-family: 'Times New Roman', serif;\">adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon‑alpha therapy, or in accelerated phase or blast crisis.</li>\n<li style=\"line-height: normal; margin: 0cm 0cm 0.0001pt 0px; font-size: 11pt; font-family: 'Times New Roman', serif;\">adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.</li>\n<li style=\"line-height: normal; margin: 0cm 0cm 0.0001pt 0px; font-size: 11pt; font-family: 'Times New Roman', serif;\">adult patients with relapsed or refractory Ph+ ALL as monotherapy.</li>\n<li style=\"line-height: normal; margin: 0cm 0cm 0.0001pt 0px; font-size: 11pt; font-family: 'Times New Roman', serif;\">adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.</li>\n<li style=\"line-height: normal; margin: 0cm 0cm 0.0001pt 0px; font-size: 11pt; font-family: 'Times New Roman', serif;\">adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR&#945; rearrangement.</li>\n</ul>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">The effect of imatinib on the outcome of bone marrow transplantation has not been determined.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Imatinib Teva <span style=\"color: black;\">is indicated for</span></p>\n<ul style=\"margin-bottom: 0cm; margin-top: 0px;\">\n<li style=\"line-height: normal; margin: 0cm 0cm 0.0001pt 0px; font-size: 11pt; font-family: 'Times New Roman', serif;\">the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).</li>\n<li style=\"line-height: normal; margin: 0cm 0cm 0.0001pt 0px; font-size: 11pt; font-family: 'Times New Roman', serif;\">the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment.</li>\n<li style=\"line-height: normal; margin: 0cm 0cm 0.0001pt 0px; font-size: 11pt; font-family: 'Times New Roman', serif;\">the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.</li>\n</ul>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">In adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression‑free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic GIST and DFSP and on recurrence-free survival in adjuvant GIST. The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re‑arrangements is very limited (see section 5.1). Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases.</p>"
                                                    }
                                                },
                                                {
                                                    "id": "592d755b-0932-ee11-bdf4-000d3aaa0146",
                                                    "title": "4.2 Posology and method of administration",
                                                    "code": {
                                                        "coding": [
                                                            {
                                                                "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                                "code": "200000029800",
                                                                "display": "4.2 Posology and method of administration"
                                                            }
                                                        ]
                                                    },
                                                    "text": {
                                                        "status": "generated",
                                                        "div": "<p>Therapy should be initiated by a physician experienced in the treatment of patients with haematological malignancies and malignant sarcomas, as appropriate.</p>"
                                                    },
                                                    "section": [
                                                        {
                                                            "id": "5a2d755b-0932-ee11-bdf4-000d3aaa0146",
                                                            "title": "Posology",
                                                            "code": {
                                                                "coding": [
                                                                    {
                                                                        "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                                        "code": "200000029801",
                                                                        "display": "Posology"
                                                                    }
                                                                ]
                                                            },
                                                            "text": {
                                                                "status": "generated",
                                                                "div": "<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Imatinib Teva 100 mg hard capsules</u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">For doses of 400&#160;mg and above (see dose recommendation below) a 400&#160;mg hard capsule is available.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Imatinib Teva 400&#160;mg hard capsules</u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">For doses other than 400&#160;mg and 800&#160;mg (see dose recommendation below) a 100&#160;mg hard capsule is available.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Posology for CML in adult patients</u></p>\n<p style=\"margin: 0.15pt 10.2pt 0.0001pt 0cm; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">T</span><span style=\"color: #231f20;\">he recommended dosage of Imatinib Teva is 400&#160;mg/day for adult patients in chronic phase CML. Chronic phase CML is defined when all of the following criteria are met: blasts&#160;&lt;&#160;15% in blood and bone marrow, peripheral blood basophils&#160;&lt;&#160;20%, platelets&#160;&gt;&#160;100&#160;x&#160;10</span><span style=\"font-size: 7.0pt; color: #231f20; position: relative; top: -5.0pt;\">9</span><span style=\"color: #231f20;\">/l</span><span style=\"color: #231f20;\">.</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 2.9pt 0.0001pt 0cm; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">T</span><span style=\"color: #231f20;\">he recommended dosage of Imatinib Teva is 600&#160;mg/day for adult patients in accelerated phase. Accelerated phase is defined by the presence of any of the following: blasts&#160;</span>&#8805;&#160;<span style=\"color: #231f20;\">15% but&#160;&lt;&#160;30% in blood or bone marrow, blasts plus promyelocytes&#160;</span>&#8805;&#160;<span style=\"color: #231f20;\">30% in blood or bone marrow (providing&#160;&lt;&#160;30% blasts), peripheral blood basophils&#160;</span>&#8805;&#160;<span style=\"color: #231f20;\">20%, platelets&#160;&lt;&#160;100&#160;x&#160;10</span><span style=\"font-size: 11pt; color: rgb(35, 31, 32); position: relative; top: -5pt;\">9</span><span style=\"color: #231f20;\">/</span><span style=\"color: #231f20;\">l unrelated to therapy.</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">The recommended dose of <span style=\"color: black;\">Imatinib Teva</span> is 600&#160;mg/day for adult patients in blast crisis. Blast crisis is defined as blasts &#8805;&#160;30% in blood or bone marrow or extramedullary disease other than hepatosplenomegaly.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Treatment duration: In clinical trials, treatment with imatinib was continued until disease progression. The effect of stopping treatment after the achievement of a complete cytogenetic response has not been investigated.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Dose increases from 400&#160;mg to 600&#160;mg or 800&#160;mg in patients with chronic phase disease, or from 600&#160;mg to a maximum of 800&#160;mg (given as 400&#160;mg twice daily) in patients with accelerated phase or blast crisis may be considered in the absence of severe adverse drug reaction and severe non‑leukaemia‑related neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time); failure to achieve a satisfactory haematological response after at least 3&#160;months of treatment; failure to achieve a cytogenetic response after 12&#160;months of treatment; or loss of a previously achieved haematological and/or cytogenetic response. Patients should be monitored closely following dose escalation given the potential for an increased incidence of adverse reactions at higher dosages.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Posology for CML in children</u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Dosing for children should be on the basis of body surface area (mg/m<sup>2</sup>). The dose of 340&#160;mg/m<sup>2</sup> daily is recommended for children with chronic phase CML and advanced phase CML (not to exceed the total dose of 800&#160;mg). Treatment can be given as a once daily dose or alternatively the daily dose may be split into two administrations &#8211; one in the morning and one in the evening. The dose recommendation is currently based on a small number of paediatric patients (see sections 5.1 and 5.2).</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">There is no experience with the treatment of children below 2&#160;years of age.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Dose increases from 340&#160;mg/m<sup>2</sup> daily to 570&#160;mg/m<sup>2</sup> daily (not to exceed the total dose of 800&#160;mg) may be considered in children in the absence of severe adverse drug reaction and severe non‑leukaemia‑related neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time); failure to achieve a satisfactory haematological response after at least 3&#160;months of treatment; failure to achieve a cytogenetic response after 12&#160;months of treatment; or loss of a previously achieved haematological and/or cytogenetic response. Patients should be monitored closely following dose escalation given the potential for an increased incidence of adverse reactions at higher dosages.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u><span style=\"color: black;\">Posology for Ph+ ALL in adult patients</span></u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">The recommended dose of Imatinib Teva is 600&#160;mg/day for adult patients with Ph+ ALL. Haematological experts in the management of this disease should supervise the therapy throughout all phases of care.</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Treatment schedule: On the basis of the existing data, imatinib has been shown to be effective and safe when administered at 600&#160;mg/day in combination with chemotherapy in the induction phase, the consolidation and maintenance phases of chemotherapy (see section 5.1) for adult patients with newly diagnosed Ph+ ALL. The duration of imatinib therapy can vary with the treatment programme selected, but generally longer exposures to imatinib have yielded better results.</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">For adult patients with relapsed or refractory Ph+ALL imatinib monotherapy at 600&#160;mg/day is safe, effective and can be given until disease progression occurs.</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u><span style=\"color: black;\">Posology for Ph+ ALL in </span></u><u>children</u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Dosing for children should be on the basis of body surface area (mg/m<sup>2</sup>). The dose of 340 mg/m<sup>2</sup> daily is recommended for children with Ph+ ALL (not to exceed the total dose of 600 mg).</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u><span style=\"color: black;\">Posology for MDS/MPD</span></u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">The recommended dose of Imatinib Teva is 400&#160;mg/day for adult patients with MDS/MPD. </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Treatment duration: In the only clinical trial performed up to now, treatment with imatinib was continued until disease progression (see section 5.1). At the time of analysis, the treatment duration was a median of 47&#160;months (24 days ‑ 60 months).</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u><span style=\"color: black;\">Posology for HES/CEL</span></u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">The recommended dose of Imatinib Teva is 100&#160;mg/day for adult patients with HES/CEL.</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Dose increase from 100&#160;mg to 400&#160;mg may be considered in the absence of adverse drug reactions if assessments demonstrate an insufficient response to therapy. </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Treatment should be continued as long as the patient continues to benefit. </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u><span style=\"color: black;\">Posology for GIST</span></u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">The recommended dose of imatinib is 400 mg/day for adult patients with unresectable and/or metastatic </span><span style=\"color: #231f20;\">malignant GIST.</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Limited data exist on the effect of dose increases from 400 mg to 600 mg or 800 mg in patients progressing at the lower dose (see section 5.1).</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Treatment duration: In clinical trials in GIST patients, treatment with imatinib was continued until disease progression. At the time of analysis, the treatment duration was a median of 7 months (7 days to 13 months). The effect of stopping treatment after achieving a response has not been investigated.</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">The recommended dose of imatinib is 400 mg/day for the adjuvant treatment of adult patients following resection of GIST. Optimal treatment duration is not yet established. Length of treatment in the clinical trial supporting this indication was 36 months (see section 5.1).</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u><span style=\"color: black;\">Posology for DFSP</span></u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">The recommended dose of Imatinib Teva is 800&#160;mg/day for adult patients with DFSP.</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Dose adjustment for adverse reactions</u></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><em>Non‑haematological adverse reactions</em></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">If a severe non‑haematological adverse reaction develops with imatinib use, treatment must be withheld until the event has resolved. Thereafter, treatment can be resumed as appropriate depending on the initial severity of the event.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">If elevations in bilirubin&#160;&gt;&#160;3&#160;x&#160;institutional&#160;upper&#160;limit&#160;of&#160;normal (IULN) or in liver transaminases&#160;&gt;&#160;5&#160;x&#160;IULN occur, imatinib should be withheld until bilirubin levels have returned to &lt;&#160;1.5&#160;x&#160;IULN and transaminase levels to &lt;&#160;2.5&#160;x&#160;IULN. Treatment with imatinib may then be continued at a reduced daily dose. In adults the dose should be reduced from 400&#160;mg to 300&#160;mg or from 600&#160;mg to&#160;400&#160;mg or from 800&#160;mg&#160;to&#160;600&#160;mg, and in children from 340&#160;to&#160;260&#160;mg/m<sup>2</sup>/day.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><em>Haematological adverse reactions</em></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Dose reduction or treatment interruption for severe neutropenia and thrombocytopenia are recommended as indicated in the table below.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Dose adjustments for neutropenia and thrombocytopenia:</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<table class=\"MsoNormalTable\" style=\"width: 464.3pt; margin-left: 5.4pt; border-collapse: collapse; border: none;\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td style=\"width: 154.75pt; border: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">HES/CEL</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">(starting dose 100&#160;mg)</span></p>\n</td>\n<td style=\"width: 154.75pt; border: solid windowtext 1.0pt; border-left: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">ANC&#160;&lt;&#160;1.0&#160;x&#160;10<sup>9</sup>/l</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">and/or</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">platelets&#160;&lt;&#160;50&#160;x&#160;10<sup>9</sup>/l</p>\n</td>\n<td style=\"width: 154.8pt; border: solid windowtext 1.0pt; border-left: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<ol style=\"margin-bottom: 0cm; margin-top: 0px;\">\n<li style=\"margin: 0cm 0cm 0.0001pt 0px; font-size: 12pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">Stop imatinib until ANC&#160;&#8805;&#160;1.5&#160;x&#160;10<sup>9</sup>/l and platelets&#160;&#8805;&#160;75&#160;x&#160;10<sup>9</sup>/l.</span></li>\n<li style=\"margin: 0cm 0cm 0.0001pt 0px; font-size: 12pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">Resume treatment with imatinib at previous dose (i.e. before severe adverse reaction).</span></li>\n</ol>\n</td>\n</tr>\n<tr>\n<td style=\"width: 154.75pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Chronic phase CML, MDS/MPD and GIST</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">(starting dose 400&#160;mg)</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">HES/CEL</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">(at dose 400 mg)</span></p>\n</td>\n<td style=\"width: 154.75pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">ANC&#160;&lt;&#160;1.0&#160;x&#160;10<sup>9</sup>/l</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">and/or</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">platelets&#160;&lt;&#160;50&#160;x&#160;10<sup>9</sup>/l</p>\n</td>\n<td style=\"width: 154.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<ol style=\"margin-bottom: 0cm; margin-top: 0px;\">\n<li style=\"margin: 0cm 0cm 0.0001pt 0px; font-size: 12pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">Stop imatinib until ANC&#160;&#8805;&#160;1.5&#160;x&#160;10<sup>9</sup>/l and platelets&#160;&#8805;&#160;75&#160;x&#160;10<sup>9</sup>/l.</span></li>\n<li style=\"margin: 0cm 0cm 0.0001pt 0px; font-size: 12pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">Resume treatment with imatinib at previous dose (i.e. before severe adverse reaction).</span></li>\n<li style=\"margin: 0cm 0cm 0.0001pt 0px; font-size: 12pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">In the event of recurrence of ANC&#160;&lt;&#160;1.0&#160;x10<sup>9</sup>/l and/or platelets&#160;&lt;&#160;50&#160;x&#160;10<sup>9</sup>/l, repeat step 1 and resume imatinib at reduced dose of 300&#160;mg.</span></li>\n</ol>\n</td>\n</tr>\n<tr>\n<td style=\"width: 154.75pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Paediatric chronic phase CML (at dose 340&#160;mg/m<sup>2</sup>)</p>\n</td>\n<td style=\"width: 154.75pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">ANC&#160;&lt;&#160;1.0&#160;x&#160;10<sup>9</sup>/l</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">and/or</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">platelets&#160;&lt;&#160;50&#160;x&#160;10<sup>9</sup>/l</p>\n</td>\n<td style=\"width: 154.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<ol style=\"margin-bottom: 0cm; margin-top: 0px;\">\n<li style=\"margin: 0cm 0cm 0.0001pt 0px; font-size: 12pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">Stop imatinib until ANC&#160;&#8805;&#160;1.5&#160;x&#160;10<sup>9</sup>/l and platelets&#160;&#8805;&#160;75&#160;x&#160;10<sup>9</sup>/l.</span></li>\n<li style=\"margin: 0cm 0cm 0.0001pt 0px; font-size: 12pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">Resume treatment with imatinib at previous dose (i.e. before severe adverse reaction).</span></li>\n<li style=\"margin: 0cm 0cm 0.0001pt 0px; font-size: 12pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">In the event of recurrence of ANC&#160;&lt;&#160;1.0&#160;x10<sup>9</sup>/l and/or platelets&#160;&lt;&#160;50&#160;x&#160;10<sup>9</sup>/l, repeat step 1 and resume imatinib at reduced dose of 260&#160;mg/m<sup>2</sup>.</span></li>\n</ol>\n</td>\n</tr>\n<tr>\n<td style=\"width: 154.75pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">A</span><span style=\"color: #231f20;\">ccelerated phase CML and </span>blast crisis <span style=\"color: black;\">and Ph+ ALL</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">(starting dose 600&#160;mg)</p>\n</td>\n<td style=\"width: 154.75pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><sup>a</sup> ANC&#160;&lt; 0.5 x 10<sup>9</sup>/l</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">and/or</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">platelets&#160;&lt;&#160;10&#160;x&#160;10<sup>9</sup>/l</p>\n</td>\n<td style=\"width: 154.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<ol style=\"margin-bottom: 0cm; margin-top: 0px;\">\n<li style=\"margin: 0cm 0cm 0.0001pt 0px; font-size: 12pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">Check whether cytopenia is related to leukaemia (marrow aspirate or biopsy).</span></li>\n<li style=\"margin: 0cm 0cm 0.0001pt 0px; font-size: 12pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">If cytopenia is unrelated to leukaemia, reduce dose of imatinib to 400&#160;mg.</span></li>\n<li style=\"margin: 0cm 0cm 0.0001pt 0px; font-size: 12pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">If cytopenia persists for 2&#160;weeks, reduce further to 300&#160;mg.</span></li>\n<li style=\"margin: 0cm 0cm 0.0001pt 0px; font-size: 12pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">If cytopenia persists for 4&#160;weeks and is still unrelated to leukaemia, stop imatinib until ANC&#160;&#8805;&#160;1&#160;x&#160;10<sup>9</sup>/l and platelets &#8805;&#160;20&#160;x&#160;10<sup>9</sup>/l, then resume treatment at 300&#160;mg.</span></li>\n</ol>\n</td>\n</tr>\n<tr>\n<td style=\"width: 154.75pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Paediatric accelerated phase CML and blast crisis</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">(starting dose 340&#160;mg/m<sup>2</sup>)</p>\n</td>\n<td style=\"width: 154.75pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><sup>a</sup> ANC&#160;&lt;&#160;0.5&#160;x&#160;10<sup>9</sup>/l</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">and/or</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">platelets&#160;&lt;&#160;10&#160;x&#160;10<sup>9</sup>/l</p>\n</td>\n<td style=\"width: 154.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<ol style=\"margin-bottom: 0cm; margin-top: 0px;\">\n<li style=\"margin: 0cm 0cm 0.0001pt 0px; font-size: 12pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">Check whether cytopenia is related to leukaemia (marrow aspirate or biopsy).</span></li>\n<li style=\"margin: 0cm 0cm 0.0001pt 0px; font-size: 12pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">If cytopenia is unrelated to leukaemia, reduce dose of imatinib to 260&#160;mg/m<sup>2</sup>.</span></li>\n<li style=\"margin: 0cm 0cm 0.0001pt 0px; font-size: 12pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">If cytopenia persists for 2&#160;weeks, reduce further to 200&#160;mg/m<sup>2</sup>.</span></li>\n<li style=\"margin: 0cm 0cm 0.0001pt 0px; font-size: 12pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">If cytopenia persists for 4&#160;weeks and is still unrelated to leukaemia, stop Imatinib until ANC&#160;&#8805;&#160;1&#160;x&#160;10<sup>9</sup>/l and platelets &#8805;&#160;20&#160;x&#160;10<sup>9</sup>/l, then resume treatment at 200&#160;mg/m<sup>2</sup>.</span></li>\n</ol>\n</td>\n</tr>\n<tr>\n<td style=\"width: 154.75pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">DFSP</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">(at dose 800&#160;mg)</p>\n</td>\n<td style=\"width: 154.75pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">ANC&#160;&lt;&#160;1.0&#160;x&#160;10<sup>9</sup>/l</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">and/or</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">platelets&#160;&lt;&#160;50&#160;x&#160;10<sup>9</sup>/l</p>\n</td>\n<td style=\"width: 154.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<ol style=\"margin-bottom: 0cm; margin-top: 0px;\">\n<li style=\"margin: 0cm 0cm 0.0001pt 0px; font-size: 12pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">Stop imatinib until ANC&#160;&#8805;&#160;1.5&#160;x&#160;10<sup>9</sup>/l and platelets&#160;&#8805;&#160;75&#160;x&#160;10<sup>9</sup>/l.</span></li>\n<li style=\"margin: 0cm 0cm 0.0001pt 0px; font-size: 12pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">Resume treatment with imatinib at 600&#160;mg.</span></li>\n<li style=\"margin: 0cm 0cm 0.0001pt 0px; font-size: 12pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">In the event of recurrence of ANC&#160;&lt;&#160;1.0&#160;x10<sup>9</sup>/l and/or platelets&#160;&lt;&#160;50&#160;x&#160;10<sup>9</sup>/l, repeat step 1 and resume imatinib at reduced dose of 400&#160;mg.</span></li>\n</ol>\n</td>\n</tr>\n<tr>\n<td style=\"width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"3\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">ANC = absolute neutrophil count</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;\"><sup><span style=\"font-size: 11.0pt;\">a</span></sup><span style=\"font-size: 11.0pt;\"> occurring after at least one month of treatment</span></p>\n</td>\n</tr>\n</tbody>\n</table>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Special populations</u></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><em>Paediatric population</em></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">There is no experience in children with CML below 2&#160;years of age and with Ph+ALL below 1&#160;year of age (see section 5.1). There is very limited experience in children with MDS/MPD, DFSP, GIST and HES/CEL.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">The safety and efficacy of imatinib in children with MDS/MPD, DFSP, GIST and HES/CEL aged less than 18&#160;years of age have not been established in clinical trials. Currently available published data are summarised in section 5.1 but no recommendation on a posology can be made.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><em>Hepatic insufficiency</em></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Imatinib is mainly metabolised through the liver. Patients with mild, moderate or severe liver dysfunction should be given the minimum recommended dose of 400&#160;mg daily. The dose can be reduced if not tolerated (see sections 4.4, 4.8 and 5.2).</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Liver dysfunction classification:</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<table class=\"MsoNormalTable\" style=\"width: 464.3pt; margin-left: 5.4pt; border-collapse: collapse; border: none;\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td style=\"width: 232.15pt; border: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Liver dysfunction</p>\n</td>\n<td style=\"width: 232.15pt; border: solid windowtext 1.0pt; border-left: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Liver function tests</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 232.15pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Mild</p>\n</td>\n<td style=\"width: 232.15pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Total bilirubin: =&#160;1.5&#160;ULN</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">AST: &gt;ULN (can be normal or &lt;&#160;ULN if total bilirubin is&#160;&gt;&#160;ULN)</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 232.15pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Moderate</p>\n</td>\n<td style=\"width: 232.15pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Total bilirubin: &gt;&#160;1.5‑3.0&#160;ULN</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">AST: any</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 232.15pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Severe</p>\n</td>\n<td style=\"width: 232.15pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Total bilirubin: &gt;&#160;3‑10&#160;ULN</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">AST: any</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">ULN = upper limit of normal for the institution</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">AST = aspartate aminotransferase</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><em>Renal insufficiency</em></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Patients with renal dysfunction or on dialysis should be given the minimum recommended dose of 400&#160;mg daily as starting dose. However, in these patients caution is recommended. The dose can be reduced if not tolerated. If tolerated, the dose can be increased for lack of efficacy (see sections 4.4 and 5.2).</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><em>Elderly</em></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Imatinib pharmacokinetics has not been specifically studied in the elderly. No significant age‑related pharmacokinetic differences have been observed in adult patients in clinical trials which included over 20% of patients age 65 and older. No specific dose recommendation is necessary in the elderly.</p>"
                                                            }
                                                        },
                                                        {
                                                            "id": "5d2d755b-0932-ee11-bdf4-000d3aaa0146",
                                                            "title": "Method of administration",
                                                            "code": {
                                                                "coding": [
                                                                    {
                                                                        "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                                        "code": "200000029803",
                                                                        "display": "Method of administration"
                                                                    }
                                                                ]
                                                            },
                                                            "text": {
                                                                "status": "generated",
                                                                "div": "<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">The prescribed dose should be administered orally with a meal and a large glass of water to minimise the risk of gastrointestinal irritations. Doses of 400&#160;mg or 600&#160;mg should be administered once daily, whereas a daily dose of 800&#160;mg should be administered as 400&#160;mg twice a day, in the morning and in the evening. For patients (children) unable to swallow the capsules, their content may be diluted in a glass of either still water or apple juice. Since studies in animals have shown reproductive toxicity, and the potential risk for the human foetus is unknown, women of child-bearing potential who open capsules should be advised to handle the contents with caution and avoid skin‑eye contact or inhalation (see section 4.6). Hands should be washed immediately after handling open capsules.</span></p>"
                                                            }
                                                        }
                                                    ]
                                                },
                                                {
                                                    "id": "632d755b-0932-ee11-bdf4-000d3aaa0146",
                                                    "title": "4.3 Contraindications",
                                                    "code": {
                                                        "coding": [
                                                            {
                                                                "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                                "code": "200000029805",
                                                                "display": "4.3 Contraindications"
                                                            }
                                                        ]
                                                    },
                                                    "text": {
                                                        "status": "generated",
                                                        "div": "<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</p>"
                                                    }
                                                },
                                                {
                                                    "id": "652d755b-0932-ee11-bdf4-000d3aaa0146",
                                                    "title": "4.4 Special warnings and precautions for use",
                                                    "code": {
                                                        "coding": [
                                                            {
                                                                "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                                "code": "200000029806",
                                                                "display": "4.4 Special warnings and precautions for use"
                                                            }
                                                        ]
                                                    },
                                                    "text": {
                                                        "status": "generated",
                                                        "div": "<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">When imatinib is co‑administered with other medicinal products, there is a potential for drug interactions. Caution should be used when taking imatinib with protease inhibitors, azole antifungals, certain macrolides, CYP3A4 substrates with a narrow therapeutic window (e.g. cyclosporine, pimozide, tacrolimus, sirolimus, ergotamine, diergotamine, fentanyl, alfentanil, terfenadine, bortezomib, docetaxel, quinidine) or warfarin and other coumarin derivatives (see section 4.5).</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Concomitant use of imatinib and medicinal products that induce CYP3A4 (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital or <em>Hypericum perforatum</em>, also known as St. John&#8217;s Wort) may significantly reduce exposure to imatinib, potentially increasing the risk of therapeutic failure. Therefore, concomitant use of strong CYP3A4 inducers and imatinib should be avoided (see section 4.5).</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Hypothyroidism</u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Clinical cases of hypothyroidism have been reported in thyroidectomy patients undergoing levothyroxine replacement during treatment with imatinib (see section 4.5). Thyroid‑stimulating hormone (TSH) levels should be closely monitored in such patients.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Hepatotoxicity</u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Metabolism of imatinib is mainly hepatic, and only 13% of excretion is through the kidneys. In patients with hepatic dysfunction (mild, moderate or severe), peripheral blood counts and liver enzymes should be carefully monitored (see sections 4.2, 4.8 and 5.2). It should be noted that GIST patients may have hepatic metastases which could lead to hepatic impairment.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Cases of liver injury, including hepatic failure and hepatic necrosis, have been observed with imatinib. When imatinib is combined with high dose chemotherapy regimens, an increase in serious hepatic reactions has been detected. Hepatic function should be carefully monitored in circumstances where imatinib is combined with chemotherapy regimens also known to be associated with hepatic dysfunction (see sections 4.5 and 4.8).</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Fluid retention</u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Occurrences of severe fluid retention (pleural effusion, oedema, pulmonary oedema, ascites, superficial oedema) have been reported in approximately 2.5% of newly diagnosed CML patients taking imatinib. Therefore, it is highly recommended that patients be weighed regularly. An unexpected rapid weight gain should be carefully investigated and if necessary appropriate supportive care and therapeutic measures should be undertaken. In clinical trials, there was an increased incidence of these events in the elderly and those with a prior history of cardiac disease. Therefore, caution should be exercised in patients with cardiac dysfunction.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Patients with cardiac disease</u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Patients with cardiac disease, risk factors for cardiac failure or history of renal failure should be monitored carefully, and any patient with signs or symptoms consistent with cardiac or renal failure should be evaluated and treated.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">In patients with hypereosinophilic syndrome (HES) with occult infiltration of HES cells within the myocardium, isolated cases of cardiogenic shock/left ventricular dysfunction have been associated with </span><span style=\"font-size: 11.0pt; color: black;\">HES cell degranulation upon </span><span style=\"font-size: 11.0pt;\">the initiation of imatinib therapy. The condition was reported to be reversible with the administration of systemic steroids, circulatory support measures and temporarily withholding imatinib. As cardiac adverse events have been reported uncommonly with imatinib, a careful assessment of the benefit/risk of imatinib therapy should be considered in the HES/CEL population before treatment initiation.</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Myelodysplastic/myeloproliferative diseases with PDGFR gene re‑arrangements could be associated with high eosinophil levels. Evaluation by a cardiology specialist, performance of an echocardiogram and determination of serum troponin should therefore be considered in patients with HES/CEL, and in patients with MDS/MPD associated with high eosinophil levels before imatinib is administered. If either is abnormal, follow‑up with a cardiology specialist and the prophylactic use of systemic steroids (1‑2&#160;mg/kg) for one to two weeks concomitantly with imatinib should be considered at the initiation of therapy.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Gastrointestinal haemorrhage</u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">In the study in patients with unresectable and/or metastatic GIST, both gastrointestinal and intra‑tumoural haemorrhages were reported (see section 4.8). Based on the available data, no predisposing factors (e.g. tumour size, tumour location, coagulation disorders) have been identified that place patients with GIST at a higher risk of either type of haemorrhage. Since increased vascularity and propensity for bleeding is a part of the nature and clinical course of GIST, standard practices and procedures for the monitoring and management of haemorrhage in all patients should be applied.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">In addition, gastric antral vascular ectasia (GAVE), a rare cause of gastrointestinal haemorrhage, has been reported in post-marketing experience in patients with CML, ALL and other diseases (see section 4.8). When needed, discontinuation of Imatinib Teva treatment may be considered.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Tumour lysis syndrome</u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Due to the possible occurrence of tumour lysis syndrome (TLS), correction of clinically significant dehydration and treatment of high uric acid levels are recommended prior to initiation of imatinib (see section 4.8).</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u><span style=\"color: black;\">Hepatitis B reactivation</span></u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Reactivation of hepatitis B in patients who are chronic carriers of this virus has occurred after these patients received BCR-ABL tyrosine kinase inhibitors. Some cases resulted in acute hepatic failure or fulminant hepatitis leading to liver transplantation or a fatal outcome.</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Patients should be tested for HBV infection before initiating treatment with Imatinib Teva. Experts in liver disease and in the treatment of hepatitis B should be consulted before treatment is initiated in patients with positive hepatitis B serology (including those with active disease) and for patients who test positive for HBV infection during treatment. Carriers of HBV who require treatment with Imatinib Teva should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy (see section 4.8).</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u><span style=\"color: black;\">Phototoxicity</span></u></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Exposure to direct sunlight should be avoided or minimised due to the risk of phototoxicity associated with imatinib treatment. Patients should be instructed to use measures such as protective clothing and sunscreen with high sun protection factor (SPF).</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u><span style=\"color: black;\">Thrombotic microangiopathy</span></u></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">BCR-ABL tyrosine kinase inhibitors (TKIs) have been associated with thrombotic microangiopathy (TMA), including individual case reports for Imatinib Teva (see section&#160;4.8). If laboratory or clinical findings associated with TMA occur in a patient receiving Imatinib Teva , treatment should be discontinued and thorough evaluation for TMA, including ADAMTS13 activity and anti-ADAMTS13-antibody determination, should be completed. If anti-ADAMTS13-antibody is elevated in conjunction with low ADAMTS13 activity, treatment with Imatinib Teva should not be resumed.</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Laboratory tests</u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Complete blood counts must be performed regularly during therapy with imatinib. Treatment of CML patients with imatinib has been associated with neutropenia or thrombocytopenia. However, the occurrence of these cytopenias is likely to be related to the stage of the disease being treated and they were more frequent in patients with accelerated phase CML or blast crisis as compared to patients with chronic phase CML. Treatment with imatinib may be interrupted or the dose may be reduced, as recommended in section 4.2.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Liver function (transaminases, bilirubin, alkaline phosphatase) should be monitored regularly in patients receiving imatinib.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">In patients with impaired renal function, imatinib plasma exposure seems to be higher than that in patients with normal renal function, probably due to an elevated plasma level of alpha‑acid&#160;glycoprotein (AGP), an imatinib‑binding protein, in these patients. Patients with renal impairment should be given the minimum starting dose. Patients with severe renal impairment should be treated with caution. The dose can be reduced if not tolerated (see section 4.2 and 5.2).</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Long-term treatment with imatinib may be associated with a clinically significant decline in renal function. Renal function should, therefore, be evaluated prior to the start of imatinib therapy and closely monitored during therapy, with particular attention to those patients exhibiting risk factors for renal dysfunction. If renal dysfunction is observed, appropriate management and treatment should be prescribed in accordance with standard treatment guidelines.</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Paediatric population</u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">There have been case reports of growth retardation occurring in children and pre‑adolescents receiving imatinib. In an observational study in the CML paediatric population, a statistically significant decrease (but of uncertain clinical relevance) in median height standard deviation scores after 12 and 24&#160;months of treatment was reported in two small subsets irrespective of pubertal status or gender. Close monitoring of growth in children under imatinib treatment is recommended (see section 4.8).</p>"
                                                    }
                                                },
                                                {
                                                    "id": "682d755b-0932-ee11-bdf4-000d3aaa0146",
                                                    "title": "4.5 Interaction with other medicinal products and other forms of interaction",
                                                    "code": {
                                                        "coding": [
                                                            {
                                                                "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                                "code": "200000029809",
                                                                "display": "4.5 Interaction with other medicinal products and other forms of interaction"
                                                            }
                                                        ]
                                                    },
                                                    "text": {
                                                        "status": "generated",
                                                        "div": "<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Active substances that may <strong>increase</strong> imatinib plasma concentrations</u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Substances that inhibit the cytochrome P450 isoenzyme CYP3A4 activity (e.g. protease inhibitors such as indinavir, lopinavir/ritonavir, ritonavir, saquinavir, telaprevir, nelfinavir, boceprevir; azole antifungals including ketoconazole, itraconazole, posaconazole, voriconazole; certain macrolides such as erythromycin, clarithromycin<span style=\"color: black;\"> </span>and telithromycin) could decrease metabolism and increase imatinib concentrations. There was a significant increase in exposure to imatinib (the mean C<sub>max</sub> and AUC of imatinib rose by 26% and 40%, respectively) in healthy subjects when it was co‑administered with a single dose of ketoconazole (a CYP3A4 inhibitor). Caution should be taken when administering imatinib with inhibitors of the CYP3A4 family.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Active substances that may <strong>decrease</strong> imatinib plasma concentrations</u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Substances that are inducers of CYP3A4 activity (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital, fosphenytoin, primidone or <em>Hypericum perforatum</em>, also known as St. John&#8217;s Wort) may significantly reduce exposure to imatinib, potentially increasing the risk of therapeutic failure. Pretreatment with multiple doses of rifampicin 600&#160;mg followed by a single 400&#160;mg dose of imatinib resulted in decrease in C<sub>max</sub> and AUC<sub>(0-&#8734;)</sub> by at least 54% and 74%, of the respective values without rifampicin treatment. Similar results were observed in patients with malignant gliomas treated with imatinib while taking enzyme‑inducing anti‑epileptic medicinal products (EIAEDs) such as carbamazepine, oxcarbazepine and phenytoin. The plasma AUC for imatinib decreased by 73% compared to patients not on EIAEDs. Concomitant use of rifampicin or other strong CYP3A4 inducers and imatinib should be avoided.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Active substances that may have their plasma concentration altered by imatinib</u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Imatinib increases the mean C<sub>max</sub> and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5‑fold, respectively, indicating an inhibition of the CYP3A4 by imatinib. Therefore, caution is recommended when administering imatinib with CYP3A4 substrates with a narrow therapeutic window (e.g. cyclosporine, pimozide,<span style=\"color: black;\"> </span>tacrolimus, sirolimus, ergotamine, diergotamine, fentanyl, alfentanil, terfenadine, bortezomib, docetaxel and quinidine). Imatinib may increase plasma concentration of other CYP3A4 metabolised drugs (e.g. triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG‑CoA reductase inhibitors, i.e. statins, etc.).</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">Because of known increased risks of bleeding in conjunction with the use of imatinib (e.g. haemorrhage), patients who require anticoagulation should receive low‑molecular‑weight or standard heparin, </span><span style=\"font-size: 11.0pt; color: black;\">instead of coumarin derivatives such as warfarin</span><span style=\"font-size: 11.0pt;\">.</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><em>In vitro</em> imatinib inhibits the cytochrome P450 isoenzyme CYP2D6 activity at concentrations similar to those that affect CYP3A4 activity. Imatinib at 400&#160;mg twice daily had an inhibitory effect on CYP2D6‑mediated metoprolol metabolism, with metoprolol C<sub>max</sub> and AUC being increased by approximately 23% (90%CI&#160;[1.16‑1.30]). Dose adjustments do not seem to be necessary when imatinib is co‑administrated with CYP2D6 substrates, however caution is advised for CYP2D6&#160;substrates with a narrow therapeutic window such as metoprolol. In patients treated with metoprolol clinical monitoring should be considered.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><em>In vitro</em>, imatinib inhibits paracetamol O‑glucuronidation with Ki value of 58.5&#160;micromol/l. This inhibition has not been observed <em>in vivo </em>after the administration of imatinib 400&#160;mg and paracetamol 1000&#160;mg. Higher doses of imatinib and paracetamol have not been studied.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Caution should therefore be exercised when using high doses of imatinib and paracetamol concomitantly.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">In thyroidectomy patients receiving levothyroxine, the plasma exposure to levothyroxine may be decreased when imatinib is co-administered (see section 4.4). Caution is therefore recommended. However, the mechanism of the observed interaction is presently unknown.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">In Ph+&#160;ALL patients, there is clinical experience of co‑administering imatinib with chemotherapy (see section 5.1), but drug-drug interactions between imatinib and chemotherapy regimens are not well characterised. Imatinib adverse events, i.e. hepatotoxicity, myelosuppression or others, may increase and it has been reported that concomitant use with L‑asparaginase could be associated with increased hepatotoxicity (see section 4.8). Therefore, the use of imatinib in combination requires special precaution.</p>"
                                                    }
                                                },
                                                {
                                                    "id": "6a2d755b-0932-ee11-bdf4-000d3aaa0146",
                                                    "title": "4.6 Fertility, pregnancy and lactation",
                                                    "code": {
                                                        "coding": [
                                                            {
                                                                "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                                "code": "200000029811",
                                                                "display": "4.6 Fertility, pregnancy and lactation"
                                                            }
                                                        ]
                                                    },
                                                    "text": {
                                                        "status": "generated",
                                                        "div": "<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u><span style=\"color: black;\">Women of childbearing potential</span></u></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Women of childbearing potential must be advised to use effective contraception during treatment and for at least 15&#160;days after stopping treatment with Imatinib Teva.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Pregnancy</u></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">There are limited data on the use of imatinib in pregnant women. There have been post-marketing reports of spontaneous abortions and infant congenital anomalies from women who have taken imatinib. Studies in animals have however shown reproductive toxicity (see section 5.3) and the potential risk for the foetus is unknown. Imatinib should not be used during pregnancy unless clearly necessary. If it is used during pregnancy, the patient must be informed of the potential risk to the foetus.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Breast-feeding</u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">There is limited information on imatinib distribution on human milk. Studies in two breast-feeding women revealed that both imatinib and its active metabolite can be distributed into human milk. The milk plasma ratio studied in a single patient was determined to be 0.5 for imatinib and 0.9 for the metabolite, suggesting greater distribution of the metabolite into the milk. Considering the combined concentration of imatinib and the metabolite and the maximum daily milk intake by infants, the total exposure would be expected to be low (~10% of a therapeutic dose). However, since the effects of low‑dose exposure of the infant to imatinib are unknown, women should not breast-feed during treatment and for at least 15&#160;days after stopping treatment with Imatinib Teva.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u><span style=\"color: black;\">Fertility</span></u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">In non-clinical studies, the fertility of male and female rats was not affected</span>, although effects on reproductive parameters were observed<span style=\"color: black;\"> (see section 5.3). Studies on patients receiving imatinib and its effect on fertility and gametogenesis have not been performed. Patients who are concerned about their fertility on imatinib treatment should consult with their physician.</span></p>"
                                                    }
                                                },
                                                {
                                                    "id": "702d755b-0932-ee11-bdf4-000d3aaa0146",
                                                    "title": "4.7 Effects on ability to drive and use machines",
                                                    "code": {
                                                        "coding": [
                                                            {
                                                                "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                                "code": "200000029815",
                                                                "display": "4.7 Effects on ability to drive and use machines"
                                                            }
                                                        ]
                                                    },
                                                    "text": {
                                                        "status": "generated",
                                                        "div": "<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Patients should be advised that they may experience undesirable effects such as dizziness, blurred vision or somnolence during treatment with imatinib. Therefore, caution should be recommended when driving a car or operating machinery.</p>"
                                                    }
                                                },
                                                {
                                                    "id": "712d755b-0932-ee11-bdf4-000d3aaa0146",
                                                    "title": "4.8 Undesirable effects",
                                                    "code": {
                                                        "coding": [
                                                            {
                                                                "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                                "code": "200000029816",
                                                                "display": "4.8 Undesirable effects"
                                                            }
                                                        ]
                                                    },
                                                    "text": {
                                                        "status": "generated",
                                                        "div": "<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Summary of the safety profile</u></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Patients with advanced stages of malignancies may have numerous confounding medical conditions that make causality of adverse reactions difficult to assess due to the variety of symptoms related to the underlying disease, its progression, and the co-administration of numerous medicinal products.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">In clinical trials in CML, drug discontinuation for drug-related adverse reactions was observed in 2.4% of newly diagnosed patients, 4% of patients in late chronic phase after failure of interferon therapy, 4% of patients in accelerated phase after failure of interferon therapy and 5% of blast crisis patients after failure of interferon therapy. In GIST the study drug was discontinued for drug-related adverse reactions in 4% of patients.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">The adverse reactions were similar in all indications, with two exceptions. There was more myelosuppression seen in CML patients than in GIST, which is probably due to the underlying disease. In the study in patients with unresectable and/or metastatic GIST, 7 (5%) patients experienced CTC grade&#160;3/4 GI bleeds (3 patients), intra‑tumoural bleeds (3 patients) or both (1 patient). GI tumour sites may have been the source of the GI bleeds (see section 4.4). GI and tumoural bleeding may be serious and sometimes fatal. The most commonly reported (&#8805;&#160;10%) drug-related adverse reactions in both settings were mild nausea, vomiting, diarrhoea, abdominal pain, fatigue, myalgia, muscle cramps and rash. Superficial oedemas were a common finding in all studies and were described primarily as periorbital or lower limb oedemas. However, these oedemas were rarely severe and may be managed with diuretics, other supportive measures, or by reducing the dose of imatinib.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">When imatinib was combined with high dose chemotherapy in Ph+&#160;ALL patients, transient liver toxicity in the form of transaminase elevation and hyperbilirubinaemia were observed. Considering the limited safety database, the adverse events thus far reported in children are consistent with the known safety profile in adult patients with Ph+ ALL. The safety database for children with Ph+ALL is very limited though no new safety concerns have been identified.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Miscellaneous adverse reactions such as pleural effusion, ascites, pulmonary oedema and rapid weight gain with or without superficial oedema may be collectively described as &#8220;fluid retention&#8221;. These reactions can usually be managed by withholding imatinib temporarily and with diuretics and other appropriate supportive care measures. However, some of these reactions may be serious or life-threatening and several patients with blast crisis died with a complex clinical history of pleural effusion, congestive heart failure and renal failure. There were no special safety findings in paediatric clinical trials.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Adverse reactions</u></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Adverse reactions reported as more than an isolated case are listed below, by system organ class and by frequency. Frequency categories are defined using the following convention: very common (&#8805;1/10), common (&#8805;1/100&#160;to&#160;&lt;1/10), uncommon (&#8805;1/1,000&#160;to&#160;&lt;1/100), rare (&#8805;1/10,000&#160;to&#160;&lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Within each frequency grouping, undesirable effects are presented in order of frequency, the most frequent first.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt 1cm; text-indent: -1cm; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Adverse reactions and their frequencies are reported in Table 1.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt 1cm; text-indent: -1cm; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"break-after: avoid; margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong>Table 1&#160;&#160;&#160;&#160; Tabulated summary of adverse reactions</strong></p>\n<p style=\"line-height: normal; break-after: avoid; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<table class=\"MsoNormalTable\" style=\"width: 464.3pt; margin-left: 5.4pt; border-collapse: collapse; border: none;\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td style=\"width: 464.3pt; border: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong>Infections and infestations</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Uncommon</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Herpes zoster, herpes simplex, nasopharyngitis, pneumonia<sup>1</sup>, sinusitis, cellulitis, upper respiratory tract infection, influenza, urinary tract infection, gastroenteritis, sepsis</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Rare</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Fungal infection</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Not known</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Hepatitis B reactivation*</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong>Neoplasm benign, malignant and unspecified (including cysts and polyps)</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Rare</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Tumour lysis syndrome</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Not known</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Tumour haemorrhage/tumour necrosis*</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: black;\">Immune system disorders</span></strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Not known</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Anaphylactic shock*</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong>Blood and lymphatic system disorders</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Very common</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Neutropenia, thrombocytopenia, anaemia</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Common</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Pancytopenia, febrile neutropenia</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Uncommon</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Thrombocythaemia, lymphopenia, bone marrow depression, eosinophilia, lymphadenopathy</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Rare</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Haemolytic anaemia<span style=\"color: black;\">, thrombotic microangiopathy</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong>Metabolism and nutrition disorders</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Common</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Anorexia</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Uncommon</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Hypokalaemia, increased appetite, hypophosphataemia, decreased appetite, dehydration, gout, hyperuricaemia, hypercalcaemia, hyperglycaemia, hyponatraemia</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Rare</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Hyperkalaemia, hypomagnesaemia</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong>Psychiatric disorders</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Common</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Insomnia</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Uncommon</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Depression, libido decreased, anxiety</p>\n</td>\n</tr>\n<tr style=\"height: 12.8pt;\">\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Rare</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Confusional state</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong>Nervous system disorders</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Very common</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Headache<sup>2</sup></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Common</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Dizziness, paraesthesia, taste disturbance, hypoaesthesia</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Uncommon</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Migraine, somnolence, syncope, peripheral neuropathy, memory impairment, sciatica, restless leg syndrome, tremor, cerebral haemorrhage</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Rare</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Increased intracranial pressure, convulsions, optic neuritis</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Not known</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Cerebral oedema*</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong>Eye disorders</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Common</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Eyelid oedema, lacrimation increased, conjunctival haemorrhage, conjunctivitis, dry eye, blurred vision</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Uncommon</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Eye irritation, eye pain, orbital oedema, scleral haemorrhage, retinal haemorrhage, blepharitis, macular oedema</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Rare</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Cataract, glaucoma, papilloedema</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Not known</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Vitreous haemorrhage*</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong>Ear and labyrinth disorders</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Uncommon</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Vertigo, tinnitus, hearing loss</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong>Cardiac disorders</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Uncommon</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Palpitations, tachycardia, cardiac failure congestive<sup>3</sup>, pulmonary oedema</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Rare</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Arrhythmia, atrial fibrillation, cardiac arrest, myocardial infarction, angina pectoris, pericardial effusion</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Not known</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Pericarditis*, cardiac tamponade*</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong>Vascular disorders<sup>4</sup></strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Common</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Flushing, haemorrhage</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Uncommon</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Hypertension, haematoma, <span style=\"color: black;\">subdural haematoma, </span>peripheral coldness, hypotension, Raynaud&#8217;s phenomenon</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Not known</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Thrombosis/embolism*</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong>Respiratory, thoracic and mediastinal disorders</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Common</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Dyspnoea, epistaxis, cough</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Uncommon</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Pleural effusion<sup>5</sup>, pharyngolaryngeal pain, pharyngitis</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Rare</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Pleuritic pain, pulmonary fibrosis, pulmonary hypertension, pulmonary haemorrhage</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Not known</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Acute respiratory failure<sup>11</sup>*, interstitial lung disease*</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong>Gastrointestinal disorders</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Very common</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Nausea, diarrhoea, vomiting, dyspepsia, abdominal pain<sup>6</sup></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Common</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Flatulence, abdominal distension, gastro-oesophageal reflux, constipation, dry mouth, gastritis</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Uncommon</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Stomatitis, mouth ulceration, gastrointestinal haemorrhage<sup>7</sup>, eructation, melaena, oesophagitis, ascites, gastric ulcer, haematemesis, cheilitis, dysphagia, pancreatitis</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Rare</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Colitis, ileus, inflammatory bowel disease</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Not known</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Ileus/intestinal obstruction*, gastrointestinal perforation*, diverticulitis*, gastric antral vascular ectasia (GAVE)*</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong>Hepatobiliary disorders</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Common</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Increased hepatic enzymes</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Uncommon</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Hyperbilirubinaemia, hepatitis, jaundice</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Rare</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Hepatic failure<sup>8</sup>, hepatic necrosis</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong>Skin and subcutaneous tissue disorders</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Very common</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Periorbital oedema, dermatitis/eczema/rash</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Common</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Pruritus, face oedema, dry skin, erythema, alopecia, night sweats, photosensitivity reaction</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Uncommon</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Rash pustular, contusion, sweating increased, urticaria, ecchymosis, increased tendency to bruise, hypotrichosis, skin hypopigmentation, dermatitis exfoliative, onychoclasis, folliculitis, petechiae, psoriasis, purpura, skin hyperpigmentation, bullous eruptions, panniculitis<sup>12</sup></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Rare</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Acute febrile neutrophilic dermatosis (Sweet&#8217;s syndrome), nail discolouration, angioneurotic oedema, rash vesicular, erythema multiforme, leucocytoclastic vasculitis, Stevens-Johnson syndrome, acute generalised exanthematous pustulosis (AGEP), pemphigus*</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Not known</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Palmoplantar erythrodysesthesia syndrome*, lichenoid keratosis*, lichen planus*, toxic epidermal necrolysis*, drug rash with eosinophilia and systemic symptoms (DRESS)*, pseudoporphyria*</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong>Musculoskeletal and connective tissue disorders</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Very common</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Muscle spasm and cramps, musculoskeletal pain including myalgia<sup>9</sup>, arthralgia, bone pain<sup>10</sup></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Common</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Joint swelling</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Uncommon</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Joint and muscle stiffness, osteonecrosis*</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Rare</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Muscular weakness, arthritis, rhabdomyolysis/myopathy</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Not known</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Growth retardation in children*</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong>Renal and urinary disorders</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Uncommon</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Renal pain, haematuria, renal failure acute, urinary frequency increased</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Not known</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Renal failure chronic</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong>Reproductive system and breast disorders</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Uncommon</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Gynaecomastia, erectile dysfunction, menorrhagia, menstruation irregular, sexual dysfunction, nipple pain, breast enlargement, scrotal oedema</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Rare</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Haemorrhagic corpus luteum/haemorrhagic ovarian cyst</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong>General disorders and administration site conditions</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Very common</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Fluid retention and oedema, fatigue</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Common</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Weakness, pyrexia, anasarca, chills, rigors</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Uncommon</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Chest pain, malaise</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong>Investigations</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Very common</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Weight increased</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Common</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Weight decreased</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Uncommon</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Blood creatinine increased, blood creatine phosphokinase increased, blood lactate dehydrogenase increased, blood alkaline phosphatase increased</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Rare</p>\n</td>\n<td style=\"width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Blood amylase increased</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt 1cm; text-indent: -1cm; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">*&#160;&#160;&#160;&#160;&#160;&#160;&#160; These types of reactions have been reported mainly from post-marketing experience with imatinib. This includes spontaneous case reports as well as serious adverse events from ongoing studies, the expanded access programmes, clinical pharmacology studies and exploratory studies in unapproved indications. Because these reactions are reported from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to imatinib exposure.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt 1cm; text-indent: -1cm; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\">1&#160;&#160;&#160;&#160;&#160;&#160;&#160; Pneumonia was reported most commonly in patients with transformed CML and in patients with GIST.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt 1cm; text-indent: -1cm; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\">2&#160;&#160;&#160;&#160;&#160;&#160;&#160; Headache was the most common in GIST patients.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt 1cm; text-indent: -1cm; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\">3&#160;&#160;&#160;&#160;&#160;&#160;&#160; On a patient-year basis, cardiac events including congestive heart failure were more commonly observed in patients with transformed CML than in patients with chronic CML.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt 1cm; text-indent: -1cm; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\">4&#160;&#160;&#160;&#160;&#160;&#160;&#160; Flushing was most common in GIST patients and bleeding (haematoma, haemorrhage) was most common in patients with GIST and with transformed CML (CML‑AP and CML‑BC).</p>\n<p style=\"margin: 0cm 0cm 0.0001pt 1cm; text-indent: -1cm; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\">5&#160;&#160;&#160;&#160;&#160;&#160;&#160; Pleural effusion was reported more commonly in patients with GIST and in patients with transformed CML (CML‑AP and CML‑BC) than in patients with chronic CML.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt 1cm; text-indent: -1cm; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\">6+7&#160;&#160;&#160; Abdominal pain and gastrointestinal haemorrhage were most commonly observed in GIST patients.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt 1cm; text-indent: -1cm; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\">8&#160;&#160;&#160;&#160;&#160;&#160;&#160; Some fatal cases of hepatic failure and of hepatic necrosis have been reported.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt 1cm; text-indent: -1cm; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\">9&#160;&#160;&#160;&#160;&#160;&#160;&#160; Musculoskeletal pain during treatment with imatinib or after discontinuation has been observed in post-marketing.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt 1cm; text-indent: -1cm; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\">10&#160;&#160;&#160;&#160;&#160; Musculoskeletal pain and related events were more commonly observed in patients with CML than in GIST patients.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt 1cm; text-indent: -1cm; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">11&#160;&#160;&#160;&#160;&#160; Fatal cases have been reported in patients with advanced disease, severe infections, severe neutropenia and other serious concomitant conditions.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt 1cm; text-indent: -1cm; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">12&#160;&#160;&#160;&#160;&#160; Including erythema nodosum.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; text-align: justify; font-size: 12pt; font-family: 'Times New Roman', serif;\"><u><span style=\"font-size: 11.0pt;\">Description of selected adverse reactions</span></u></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; text-align: justify; font-size: 12pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; text-align: justify; font-size: 12pt; font-family: 'Times New Roman', serif;\"><em><span style=\"font-size: 11.0pt;\">Hepatitis B reactivation</span></em></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; text-align: justify; font-size: 12pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">Hepatitis B reactivation has been reported in association with BCR-ABL TKIs. Some cases resulted in acute hepatic failure or fulminant hepatitis leading to liver transplantation or a fatal outcome (see section 4.4).</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Laboratory test abnormalities</u></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><em>Haematology</em></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">In CML, cytopenias, particularly neutropenia and thrombocytopenia, have been a consistent finding in all studies, with the suggestion of a higher frequency at high doses &#8805;&#160;750&#160;mg (phase I study). However, the occurrence of cytopenias was also clearly dependent on the stage of the disease, the frequency of grade&#160;3 or 4 neutropenias (ANC&#160;&lt;&#160;1.0&#160;x&#160;10<sup>9</sup>/l) and thrombocytopenias (platelet&#160;count&#160;&lt;&#160;50&#160;x&#160;10<sup>9</sup>/l) being between 4 and 6 times higher in blast crisis and accelerated phase (59‑64% and 44‑63% for neutropenia and thrombocytopenia, respectively) as compared to newly diagnosed patients in chronic phase CML (16.7% neutropenia and 8.9% thrombocytopenia). In newly diagnosed chronic phase CML grade&#160;4 neutropenia (ANC&#160;&lt;&#160;0.5&#160;x&#160;10<sup>9</sup>/l) and thrombocytopenia (platelet count &lt;&#160;10&#160;x&#160;10<sup>9</sup>/l) were observed in 3.6% and &lt;&#160;1% of patients, respectively. The median duration of the neutropenic and thrombocytopenic episodes usually ranged from 2 to 3 weeks, and from 3 to 4 weeks, respectively. These events can usually be managed with either a reduction of the dose or an interruption of treatment with imatinib, but can in rare cases lead to permanent discontinuation of treatment. In paediatric CML patients the most frequent toxicities observed were grade&#160;3 or 4 cytopenias involving neutropenia, thrombocytopenia and anaemia. These generally occur within the first several months of therapy.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">In the study in patients with unresectable and/or metastatic GIST, grade&#160;3 and 4 anaemia was reported in 5.4% and 0.7% of patients, respectively, and may have been related to gastrointestinal or intra-tumoural bleeding in at least some of these patients. Grade&#160;3 and 4 neutropenia was seen in 7.5% and 2.7% of patients, respectively, and grade&#160;3 thrombocytopenia in 0.7% of patients. No patient developed grade&#160;4 thrombocytopenia. The decreases in white blood cell (WBC) and neutrophil counts occurred mainly during the first six weeks of therapy, with values remaining relatively stable thereafter.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><em>Biochemistry</em></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Severe elevation of transaminases (&lt;5%) or bilirubin (&lt;1%) was seen in CML patients and was usually managed with dose reduction or interruption (the median duration of these episodes was approximately one week). Treatment was discontinued permanently because of liver laboratory abnormalities in less than 1% of CML patients. In GIST patients (study B2222), 6.8% of grade&#160;3 or 4 ALT (alanine aminotransferase) elevations and 4.8% of grade&#160;3 or 4 AST (aspartate aminotransferase) elevations were observed. Bilirubin elevation was below 3%.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">There have been cases of cytolytic and cholestatic hepatitis and hepatic failure; in some of them outcome was fatal, including one patient on high dose paracetamol.</p>"
                                                    },
                                                    "section": [
                                                        {
                                                            "id": "732d755b-0932-ee11-bdf4-000d3aaa0146",
                                                            "title": "Reporting of suspected adverse reactions",
                                                            "code": {
                                                                "coding": [
                                                                    {
                                                                        "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                                        "code": "200000029818",
                                                                        "display": "Reporting of suspected adverse reactions"
                                                                    }
                                                                ]
                                                            },
                                                            "text": {
                                                                "status": "generated",
                                                                "div": "<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions <span style=\"background: lightgrey;\">via the national reporting system listed in </span><a style=\"color: blue; text-decoration: underline;\" href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span style=\"background: lightgrey;\">Appendix V</span></a>.</p>"
                                                            }
                                                        }
                                                    ]
                                                },
                                                {
                                                    "id": "742d755b-0932-ee11-bdf4-000d3aaa0146",
                                                    "title": "4.9 Overdose",
                                                    "code": {
                                                        "coding": [
                                                            {
                                                                "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                                "code": "200000029819",
                                                                "display": "4.9 Overdose"
                                                            }
                                                        ]
                                                    },
                                                    "text": {
                                                        "status": "generated",
                                                        "div": "<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">Experience with doses higher than the recommended therapeutic dose is limited. Isolated cases of imatinib overdose have been reported spontaneously and in the literature. In the event of overdose the patient should be observed and appropriate symptomatic treatment given. Generally the reported outcome in these cases was &#8220;improved&#8221; or &#8220;recovered&#8221;. Events that have been reported at different dose ranges are as follows:</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><u><span style=\"font-size: 11.0pt;\">Adult population</span></u></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">1200&#160;mg to 1600&#160;mg (duration varying between 1 to 10&#160;days): Nausea, vomiting, diarrhoea, rash, erythema, oedema, swelling, fatigue, muscle spasms, thrombocytopenia, pancytopenia, abdominal pain, headache, decreased appetite.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">1800&#160;mg to 3200&#160;mg (as high as 3200&#160;mg daily for 6&#160;days): Weakness, myalgia, increased creatine phosphokinase, increased bilirubin, gastrointestinal pain. </span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">6400&#160;mg (single dose): One case reported in the literature of one patient who experienced nausea, vomiting, abdominal pain, pyrexia, facial swelling, decreased neutrophil count, increased transaminases.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">8&#160;g to 10&#160;g (single dose): Vomiting and gastrointestinal pain have been reported.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><u><span style=\"font-size: 11.0pt;\">Paediatric population</span></u></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">One 3‑year‑old male exposed to a single dose of 400&#160;mg experienced vomiting, diarrhoea and anorexia and another 3‑year‑old male exposed to a single dose of 980&#160;mg experienced decreased white blood cell count and diarrhoea.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">In the event of overdose, the patient should be observed and appropriate supportive treatment given.</p>"
                                                    }
                                                }
                                            ]
                                        },
                                        {
                                            "id": "762d755b-0932-ee11-bdf4-000d3aaa0146",
                                            "title": "5. PHARMACOLOGICAL PROPERTIES",
                                            "code": {
                                                "coding": [
                                                    {
                                                        "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                        "code": "200000029821",
                                                        "display": "5. PHARMACOLOGICAL PROPERTIES"
                                                    }
                                                ]
                                            },
                                            "text": {
                                                "status": "generated"
                                            },
                                            "section": [
                                                {
                                                    "id": "772d755b-0932-ee11-bdf4-000d3aaa0146",
                                                    "title": "5.1 Pharmacodynamic properties",
                                                    "code": {
                                                        "coding": [
                                                            {
                                                                "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                                "code": "200000029822",
                                                                "display": "5.1 Pharmacodynamic properties"
                                                            }
                                                        ]
                                                    },
                                                    "text": {
                                                        "status": "generated",
                                                        "div": "<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Pharmacotherapeutic group: Antineoplastic agents, BCR-ABL tyrosine kinase inhibitors, ATC code: L01EA01</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u><span style=\"color: black;\">Mechanism of action</span></u></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Imatinib is a small molecule protein-tyrosine kinase inhibitor that potently inhibits the activity of the Bcr‑Abl tyrosine kinase (TK), as well as several receptor TKs: </span>Kit, the receptor for stem cell factor (SCF) coded for by the c-Kit proto-oncogene, <span style=\"color: black;\">the discoidin domain receptors (DDR1 and DDR2), the colony stimulating factor receptor (CSF-1R) and the platelet-derived growth factor receptors alpha and beta (PDGFR-alpha and PDGFR-beta). Imatinib can also inhibit cellular events mediated by activation of these receptor kinases.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Pharmacodynamic effects</u></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Imatinib is a protein-tyrosine kinase inhibitor which potently inhibits the Bcr‑Abl tyrosine kinase at the <em>in vitro</em>, cellular and <em>in vivo </em>levels. The compound selectively inhibits proliferation and induces apoptosis in Bcr‑Abl positive cell lines as well as fresh leukaemic cells from Philadelphia chromosome positive CML and acute lymphoblastic leukaemia (ALL) patients.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><em>In vivo </em>the compound shows anti-tumour activity as a single agent in animal models using Bcr‑Abl positive tumour cells.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF), PDGF-R, and <span style=\"color: #231f20;\">stem cell factor (SCF), c-Kit, and </span>inhibits PDGF- and SCF- mediated cellular events. <em><span style=\"color: #231f20;\">In vitro</span></em><span style=\"color: #231f20;\">, imatinib inhibits proliferation and induces apoptosis in gastrointestinal stromal tumour (GIST) cells, which express an activating <em>kit </em>mutation. </span>Constitutive activation of the PDGF receptor or the Abl protein tyrosine kinases as a consequence of fusion to diverse partner proteins or constitutive production of PDGF have been implicated in the pathogenesis of MDS/MPD, HES/CEL and DFSP. Imatinib inhibits signalling and proliferation of cells driven by dysregulated PDGFR and Abl kinase activity.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Clinical studies in chronic myeloid leukaemia</u></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">The effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression‑free survival. <span style=\"color: #231f20;\">Except in newly diagnosed chronic phase CML,</span> there are no controlled trials demonstrating a clinical benefit, such as improvement in disease-related symptoms or increased survival.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Three large, international, open-label, non-controlled phase II studies were conducted in patients with Philadelphia chromosome positive (Ph+) CML <span style=\"color: #231f20;\">i</span><span style=\"color: #231f20;\">n advanced, blast or accelerated phase disease, other Ph+ leukaemias or with CML in the chronic phase but failing prior interferon-alpha (IFN) therapy. One large, open-label, multicentre, international randomised phase III study has been conducted in patients with newly diagnosed Ph+ CML. </span>In addition, children have been treated in two phase I studies and one phase II study.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">In all clinical studies 38‑40% of patients were &#8805;&#160;60 years of age and 10‑12% of patients were &#8805;&#160;70 years of age.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 2.2pt 0.0001pt 0cm; line-height: 102%; font-size: 11pt; font-family: 'Times New Roman', serif;\"><em><span style=\"color: #231f20;\">C</span><span style=\"color: #231f20;\">hronic phase, newly diagnosed</span></em></p>\n<p style=\"margin: 0cm 2.2pt 0.0001pt 0cm; line-height: 102%; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">T</span><span style=\"color: #231f20;\">his phase III study in adult patients compared treatment with either single-agent imatinib or a combination of interferon-alpha (IFN) plus cytarabine (Ara-C). Patients showing lack of response (lack of complete haematological response (CHR) at 6&#160;months, increasing WBC, no major cytogenetic response (MCyR) at 24&#160;months), loss of response (loss of CHR or MCyR) or severe intolerance to treatment were allowed to cross over to the alternative treatment arm. In the imatinib arm, patients were treated with 400&#160;mg daily. In the IFN arm, patients were treated with <span style=\"position: relative; top: .5pt;\">a target dose of IFN of </span></span><span style=\"line-height: 102%; color: #231f20; position: relative; top: .5pt;\">5&#160;MIU/m<sup>2</sup>/day subcutaneously in combination with subcutaneous Ara-C </span><span style=\"line-height: 102%; color: #231f20;\">20&#160;mg/m<sup>2</sup>/day for 10&#160;days/month.</span></p>\n<p style=\"margin: 0.25pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"margin: 0cm 2.25pt 0.0001pt 0cm; line-height: 102%; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">A total of 1.106&#160;patients were randomised, 553 to each arm. Baseline characteristics were well balanced between the two arms. Median age was 51&#160;years (range 18&#8211;70&#160;years), with 21.9% of patients&#160;&#8805;&#160;60 years of age. There were 59% males and 41% females; 89.9% caucasian and 4.7% black patients. Seven years after the last patient had been recruited, the median duration of first-line treatment was 82 and 8&#160;months in the </span><span style=\"color: #231f20;\">imatinib</span><span style=\"color: #231f20;\"> and IFN arms, respectively. The median duration of second‑line treatment with </span><span style=\"color: #231f20;\">imatinib</span><span style=\"color: #231f20;\"> was 64&#160;months. Overall, in patients receiving first‑line </span><span style=\"color: #231f20;\">imatinib</span><span style=\"color: #231f20;\">, the average daily dose delivered was 406&#160;&#177;76&#160;mg. The primary efficacy endpoint of the study is progression-free survival. Progression was defined as any of the following events: progression to accelerated phase or blast crisis, death, loss of CHR or MCyR, or in patients not achieving a CHR an increasing WBC despite appropriate therapeutic management. Major cytogenetic response, haematological response, molecular response (evaluation of minimal residual disease), time to accelerated phase or blast crisis and survival are main secondary endpoints. Response data are shown in Table 2.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"margin: 0cm -1pt 0.0001pt 0cm; line-height: 12.4pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: #231f20; position: relative; top: .5pt;\">T</span><span style=\"color: #231f20; position: relative; top: .5pt;\">able 2&#160;&#160;&#160; Response in newly diagnosed CML Study (84-month data)</span></strong></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<table class=\"MsoNormalTable\" style=\"width: 474.8pt; margin-left: 5.4pt; border-collapse: collapse;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td style=\"width: 157.35pt; border: solid windowtext 1.0pt; border-right: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0.2pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0.75pt 0cm 0.0001pt; break-after: avoid; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: #231f20;\">(B</span><span style=\"color: #231f20;\">est response rates)</span></strong></p>\n</td>\n<td style=\"width: 158.75pt; border-top: solid windowtext 1.0pt; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: none; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0.2pt 49.65pt 0.0001pt 46.25pt; text-align: center; line-height: normal; break-after: avoid; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">Imatinib</span></p>\n<p style=\"margin: 0.75pt 0cm 0.0001pt; text-align: center; break-after: avoid; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">n=553</span></p>\n</td>\n<td style=\"width: 158.7pt; border: solid windowtext 1.0pt; border-left: none; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0.2pt 37.4pt 0.0001pt 38.05pt; text-align: center; line-height: normal; break-after: avoid; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">I</span><span style=\"color: #231f20;\">F</span><span style=\"color: #231f20;\">N+A</span><span style=\"color: #231f20;\">r</span><span style=\"color: #231f20;\">a</span><span style=\"color: #231f20;\">-</span><span style=\"color: #231f20;\">C</span></p>\n<p style=\"margin: 0.75pt 0cm 0.0001pt; text-align: center; break-after: avoid; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">n=553</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 157.35pt; border: none; border-left: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0.2pt -1pt 0.0001pt 0cm; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: #231f20;\">H</span><span style=\"color: #231f20;\">aematological </span><span style=\"color: #231f20;\">r</span><span style=\"color: #231f20;\">e</span><span style=\"color: #231f20;\">sponse</span></strong></p>\n<p style=\"margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">CH</span><span style=\"color: #231f20;\">R rate n (%)</span></p>\n<p style=\"margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">&#160;&#160;&#160;&#160;&#160;&#160; [95% CI]</span></p>\n<p style=\"margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n</td>\n<td style=\"width: 158.75pt; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"margin: 0.75pt 0cm 0.0001pt; text-align: center; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">534 (96.6%)*</span></p>\n<p style=\"margin: 0.75pt 0cm 0.0001pt; text-align: center; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">[94.7%, 97.9%]</span></p>\n</td>\n<td style=\"width: 158.7pt; border: none; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"margin: 0.75pt 0cm 0.0001pt; text-align: center; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">313 (56.6%)*</span></p>\n<p style=\"margin: 0.75pt 0cm 0.0001pt; text-align: center; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">[52.4%, 60.8%]</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 157.35pt; border: none; border-left: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: #231f20;\">Cytogenetic response</span></strong></p>\n</td>\n<td style=\"width: 158.75pt; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n</td>\n<td style=\"width: 158.7pt; border: none; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 157.35pt; border: none; border-left: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">Major response n (%)</span></p>\n<p style=\"margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">&#160;&#160;&#160;&#160;&#160;&#160; [95% CI]</span></p>\n<p style=\"margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">&#160;&#160;&#160;&#160;&#160;&#160; Complete CyR n (%)</span></p>\n<p style=\"margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">&#160;&#160;&#160;&#160;&#160;&#160; Partial CyR n (%)</span></p>\n<p style=\"margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">&#160;</span></p>\n</td>\n<td style=\"width: 158.75pt; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0cm -1pt 0.0001pt 0cm; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">490 (88.6%)*</span></p>\n<p style=\"margin: 0cm -1pt 0.0001pt 0cm; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">[85.7%, 91.1%]</span></p>\n<p style=\"margin: 0cm -1pt 0.0001pt 0cm; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">456 (82.5%)*</span></p>\n<p style=\"text-align: center; margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">34 (6.1%)</span></p>\n</td>\n<td style=\"width: 158.7pt; border: none; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0cm -1pt 0.0001pt 0cm; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">129 (23.3%)*</span></p>\n<p style=\"margin: 0cm -1pt 0.0001pt 0cm; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">[19.9%, 27.1%]</span></p>\n<p style=\"margin: 0cm -1pt 0.0001pt 0cm; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">64 (11.6%)*</span></p>\n<p style=\"margin: 0cm -1.15pt 0.0001pt 0cm; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">65 (11.8%)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 7.0cm; border: none; border-left: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: #231f20;\">Molecular response**</span></strong></p>\n</td>\n<td style=\"width: 158.75pt; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">&#160;</span></p>\n</td>\n<td style=\"width: 117.6pt; border: none; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">&#160;</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 7.0cm; border-top: none; border-left: solid windowtext 1.0pt; border-bottom: solid windowtext 1.0pt; border-right: none; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">Major response at 12 months (%)</span></p>\n<p style=\"margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">Major response at 24 months (%)</span></p>\n<p style=\"margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">Major response at 84 months (%)</span></p>\n</td>\n<td style=\"width: 158.75pt; border: none; border-bottom: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">153/305=50.2%</span></p>\n<p style=\"margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">73/104=70.2%</span></p>\n<p style=\"margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">102/116=87.9%</span></p>\n</td>\n<td style=\"width: 117.6pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">8/83=9.6%</span></p>\n<p style=\"margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">3/12=25%</span></p>\n<p style=\"margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">3/4=75%</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 474.8pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" colspan=\"5\" valign=\"top\">\n<p style=\"margin: 0cm -1pt 0.0001pt 0cm; line-height: 12.05pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">* p&lt;0.001, Fischer&#8217;s exact test</span></p>\n<p style=\"margin: 0.3pt -1pt 0.0001pt 0cm; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">** molecular response percentages are based on available samples</span></p>\n<p style=\"margin: 0.2pt -1pt 0.0001pt 0cm; line-height: 13.3pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: #231f20; position: relative; top: .5pt;\">H</span><span style=\"color: #231f20; position: relative; top: .5pt;\">aematological </span><span style=\"color: #231f20; position: relative; top: .5pt;\">r</span><span style=\"color: #231f20; position: relative; top: .5pt;\">e</span><span style=\"color: #231f20; position: relative; top: .5pt;\">sponse criteria (all responses to be confirmed after </span></strong><strong>&#8805;<span style=\"color: #231f20; position: relative; top: .5pt;\"> </span><span style=\"color: #231f20; position: relative; top: .5pt;\">4 weeks):</span></strong></p>\n<p style=\"margin: 0.05pt 25.55pt 0.0001pt 0cm; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">WBC &lt; 10 x 10</span><span style=\"font-size: 7.0pt; color: #231f20; position: relative; top: -5.0pt;\">9</span><span style=\"color: #231f20;\">/l</span><span style=\"color: #231f20;\">, platelet &lt; 450 x 10</span><span style=\"font-size: 7.0pt; color: #231f20; position: relative; top: -5.0pt;\">9</span><span style=\"color: #231f20;\">/l</span><span style=\"color: #231f20;\">, myelocyte+metamyelocyte &lt; 5% in blood, no blasts and promyelocytes in blood, basophils &lt; 20%, no extramedullary involvement</span></p>\n<p style=\"margin: 0.3pt 17.35pt 0.0001pt 0cm; line-height: 102%; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: #231f20;\">C</span><span style=\"color: #231f20;\">ytogenetic response criteria:</span></strong><span style=\"color: #231f20;\"> </span><span style=\"color: #231f20;\">complete (0% Ph+ metaphases), partial (1&#8211;35%), minor (36&#8211;65%) or minimal (66&#8211;95%). A major response (0&#8211;35%) combines both complete and partial responses. <strong>Major molecular response criteria:</strong> in the peripheral blood reduction of &#8805; 3 logarithms in the amount of Bcr‑Abl transcripts (measured by real-time quantitative reverse transcriptase PCR assay) over a standardised baseline.</span></p>\n</td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin: 0cm 10.2pt 0.0001pt 0cm; line-height: 102%; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">&#160;</span></p>\n<p style=\"margin: 0cm 10.2pt 0.0001pt 0cm; line-height: 102%; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">Rates of complete haematological response, major cytogenetic response and complete cytogenetic response on first-line treatment were estimated using the Kaplan-Meier approach, for which non‑responses were censored at the date of last examination. Using this approach, the estimated cumulative response rates for first-line treatment with imatinib improved from 12 months of therapy to 84&#160;months of therapy as follows: CHR from 96.4% to 98.4% and CCyR from 69.5% to 87.2%, respectively.</span></p>\n<p style=\"margin: 0cm 10.2pt 0.0001pt 0cm; line-height: 102%; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">&#160;</span></p>\n<p style=\"margin: 0cm 10.2pt 0.0001pt 0cm; line-height: 102%; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">With 7&#160;years follow-up, there were 93&#160;(16.8%) progression events in the imatinib arm: 37&#160;(6.7%) involving progression to accelerated phase/blast crisis, 31&#160;(5.6%) loss of MCyR, 15&#160;(2.7%) loss of CHR or increase in WBC, and 10&#160;(1.8%) CML unrelated deaths. In contrast, there were 165&#160;(29.8%) events in the IFN+Ara-C arm, of which 130 occurred during first-line treatment with IFN+Ara-C.</span></p>\n<p style=\"margin: 0.95pt 0cm 0.0001pt; line-height: 12pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"margin: 0cm 10.2pt 0.0001pt 0cm; line-height: 102%; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">The estimated rate of patients free of progression to accelerated phase or blast crisis at 84&#160;months was significantly higher in the imatinib arm compared to the IFN arm (92.5% versus 85.1%, p&lt;0.001). The annual rate of progression to accelerated phase or blast crisis decreased with time on therapy and was less than 1% annually in the fourth and fifth years. The estimated rate of progression-free survival at 84&#160;months was 81.2% in the imatinib arm and 60.6% in the control arm (p&lt;0.001). The yearly rates of progression of any type for imatinib also decreased over time.</span></p>\n<p style=\"margin: 0cm 10.2pt 0.0001pt 0cm; line-height: 102%; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">&#160;</span></p>\n<p style=\"margin: 0cm 10.2pt 0.0001pt 0cm; line-height: 102%; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">A total of 71&#160;(12.8%) and 85&#160;(15.4%) patients died in the imatinib and IFN+Ara-C groups, respectively. At 84 months the estimated overall survival is 86.4%&#160;(83,&#160;90) vs. 83.3%&#160;(80,&#160;87) in the randomised imatinib and the IFN+Ara-C groups, respectively (p=0.073, log-rank test). This time‑to‑event endpoint is strongly affected by the high crossover rate from IFN+Ara-C to imatinib. The effect of imatinib treatment on survival in chronic phase, newly diagnosed CML has been further examined in a retrospective analysis of the above reported imatinib data with the primary data from another Phase III study using IFN+Ara-C (n=325) in an identical regimen. In this retrospective analysis, the superiority of imatinib over IFN+Ara-C in overall survival was demonstrated (p&lt;0.001); within 42&#160;months, 47&#160;(8.5%) imatinib patients and 63&#160;(19.4%) IFN+Ara-C patients had died.</span></p>\n<p style=\"margin: 0.95pt 0cm 0.0001pt; line-height: 12pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"margin: 0cm 8.1pt 0.0001pt 0cm; line-height: 102%; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">T</span><span style=\"color: #231f20;\">he degree of cytogenetic response and molecular response had a clear effect on long-term outcomes in patients on imatinib. Whereas an estimated 96% (93%) of patients with CCyR (PCyR) at 12&#160;months were free of progression to accelerated phase/blast crisis at 84&#160;months, only 81% of patients without MCyR at 12&#160;months were free of progression to advanced CML at 84&#160;months (p&lt;0.001 overall, p=0.25 between CCyR and PCyR). For patients with reduction in Bcr‑Abl transcripts of at least 3&#160;logarithms at 12&#160;months, the probability of remaining free from progression to accelerated phase/blast crisis was 99% at 84&#160;months. Similar findings were found based on a 18‑months landmark analysis.</span></p>\n<p style=\"margin: 0.95pt 0cm 0.0001pt; line-height: 12pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"margin: 0cm 4.5pt 0.0001pt 0cm; line-height: 102%; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">I</span><span style=\"color: #231f20;\">n this study, dose escalations were allowed from 400&#160;mg daily to 600&#160;mg daily, then from 600&#160;mg daily to 800&#160;mg daily. After 42&#160;months of follow-up, 11&#160;patients experienced a confirmed loss (within 4&#160;weeks) of their cytogenetic response. Of these 11&#160;patients, 4&#160;patients escalated up to 800&#160;mg daily, 2&#160;of whom regained a cytogenetic response (1&#160;partial and 1&#160;complete, the latter also achieving a molecular response), while of the 7&#160;patients who did not escalate the dose, only one regained a complete cytogenetic response. The percentage of some adverse reactions was higher in the 40&#160;patients in whom the dose was increased to 800&#160;mg daily compared to the population of patients before dose increase (n=551). The more frequent adverse reactions included gastrointestinal haemorrhages, conjunctivitis and elevation of transaminases or bilirubin. Other adverse reactions were reported with lower or equal frequency.</span></p>\n<p style=\"margin: 0.95pt 0cm 0.0001pt; line-height: 12pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"margin: 0cm 10.8pt 0.0001pt 0cm; line-height: 101%; font-size: 11pt; font-family: 'Times New Roman', serif;\"><em><span style=\"color: #231f20;\">C</span><span style=\"color: #231f20;\">hronic phase, Interferon failure</span></em></p>\n<p style=\"margin: 0cm 10.8pt 0.0001pt 0cm; line-height: 101%; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">532 adult patients were treated at a starting dose of 400 mg. The patients were distributed in three main categories: haematological failure (29%), cytogenetic failure (35%), or intolerance to interferon (36%). Patients had received a median of 14 months of prior IFN therapy at doses &#8805;&#160;25&#160;x&#160;10</span><span style=\"font-size: 7.0pt; line-height: 101%; color: #231f20; position: relative; top: -5.0pt;\">6&#160;</span><span style=\"color: #231f20;\">I</span><span style=\"color: #231f20;\">U</span><span style=\"color: #231f20;\">/</span><span style=\"color: #231f20;\">w</span><span style=\"color: #231f20;\">eek and were all in late chronic phase, with a median time from diagnosis of 32 months. The primary efficacy variable of the study was the rate of major cytogenetic response (complete plus partial response, 0&#160;to&#160;35% Ph+ metaphases in the bone marrow).</span></p>\n<p style=\"margin: 0.1pt 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif; line-height: 13pt;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"margin: 0cm 9.75pt 0.0001pt 0cm; line-height: 102%; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">I</span><span style=\"color: #231f20;\">n this study 65% of the patients achieved a major cytogenetic response that was complete in 53% (confirmed 43%) of patients (Table 3). A complete haematological response was achieved in 95% of patients.</span></p>\n<p style=\"margin: 0cm 9.75pt 0.0001pt 0cm; line-height: 102%; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"margin: 0cm 9.75pt 0.0001pt 0cm; line-height: 102%; font-size: 11pt; font-family: 'Times New Roman', serif;\"><em><span style=\"color: #231f20;\">Accelerated phase</span></em></p>\n<p style=\"margin: 0cm 9.75pt 0.0001pt 0cm; line-height: 102%; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">235 adult patients with accelerated phase disease were enrolled. The first 77 patients were started at 400&#160;mg, the protocol was subsequently amended to allow higher dosing and the remaining 158 patients were started at 600&#160;mg.</span></p>\n<p style=\"margin: 0.95pt 0cm 0.0001pt; line-height: 12pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"margin: 0cm 11.05pt 0.0001pt 0cm; line-height: 102%; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">T</span><span style=\"color: #231f20;\">he primary efficacy variable was the rate of haematological response, reported as either complete haematological response, no evidence of leukaemia (i.e. clearance of blasts from the marrow and the blood, but without a full peripheral blood recovery as for complete responses), or return to chronic phase CML. A confirmed haematological response was achieved in 71.5% of patients (Table 3). Importantly, 27.7% of patients also achieved a major cytogenetic response, which was complete in 20.4% (confirmed 16%) of patients. For the patients treated at 600&#160;mg, the current estimates for median progression-free-survival and overall survival were 22.9 and 42.5 months, respectively.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif; line-height: 13pt;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif; line-height: 13pt;\"><em>Myeloid blast crisis</em></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif; line-height: 13pt;\">260 patients with myeloid blast crisis were enrolled. 95&#160;(37%) had received prior chemotherapy for treatment of either accelerated phase or blast crisis (&#8220;pretreated patients&#8221;) whereas 165&#160;(63%) had not (&#8220;untreated patients&#8221;). The first 37 patients were started at 400&#160;mg, the protocol was subsequently amended to allow higher dosing and the remaining 223 patients were started at 600&#160;mg.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif; line-height: 13pt;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">The primary efficacy variable was the rate of haematological response, reported as either complete haematological response, no evidence of leukaemia, or return to chronic phase CML using the same criteria as for the study in accelerated phase. In this study, 31% of patients achieved a haematological response (36% in previously untreated patients and 22% in previously treated patients). The rate of response was also higher in the patients treated at 600&#160;mg (33%) as compared to the patients treated at 400&#160;mg (16%, p=0.0220). The current estimate of the median survival of the previously untreated and treated patients was 7.7 and 4.7&#160;months, respectively.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif; line-height: 13pt;\"><em>Lymphoid blast crisis</em></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif; line-height: 13pt;\">A limited number of patients were enrolled in phase I studies (n=10). The rate of haematological response was 70% with a duration of 2<strong><em>‑</em></strong>3 months.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif; line-height: 13pt;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif; line-height: 13pt;\"><strong>Table 3&#160;&#160;&#160;&#160; Response in adult CML studies</strong></p>\n<p style=\"margin: 0cm -0.1pt 0.0001pt 0cm; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<table class=\"MsoNormalTable\" style=\"margin-left: 6.85pt; border-collapse: collapse;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr style=\"height: 65.25pt;\">\n<td style=\"width: 154.75pt; border: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 12.0pt;\">&#160;</span></p>\n</td>\n<td style=\"width: 94.75pt; border: solid #231F20 1.0pt; border-left: none; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 18.95pt 0.0001pt 20.05pt; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">Study 0110</span></p>\n<p style=\"margin: 0.3pt 11.95pt 0.0001pt 13.05pt; text-align: center; text-indent: -0.1pt; line-height: 102%; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">37-month data Chronic phase, IFN failure (n=532)</span></p>\n</td>\n<td style=\"width: 99.3pt; border: solid #231F20 1.0pt; border-left: none; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 21.35pt 0.0001pt 22.25pt; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">Study 0109</span></p>\n<p style=\"margin: 0.3pt 7.2pt 0.0001pt 7.9pt; text-align: center; text-indent: 0.2pt; line-height: 102%; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">40.5-month data Accelerated phase (n=235)</span></p>\n</td>\n<td style=\"width: 96.35pt; border: solid #231F20 1.0pt; border-left: none; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 19.8pt 0.0001pt 20.8pt; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">Study 0102</span></p>\n<p style=\"margin: 0.3pt 14pt 0.0001pt 15.05pt; text-align: center; line-height: 102%; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">38-month data Myeloid blast crisis</span></p>\n<p style=\"margin: 0cm 27.15pt 0.0001pt 28.25pt; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">(</span><span style=\"color: #231f20;\">n=260)</span></p>\n</td>\n</tr>\n<tr style=\"height: 13.45pt;\">\n<td style=\"width: 154.75pt; border: solid #231F20 1.0pt; border-top: none; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 12.0pt;\">&#160;</span></p>\n</td>\n<td style=\"width: 290.4pt; border-top: none; border-left: none; border-bottom: solid #231F20 1.0pt; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" colspan=\"3\" valign=\"top\">\n<p style=\"margin: 0cm 95.95pt 0.0001pt 96.9pt; text-align: center; line-height: 12.85pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">% of patients (CI</span><span style=\"font-size: 7.0pt; color: #231f20; position: relative; top: 1.5pt;\">95%</span><span style=\"color: #231f20;\">)</span></p>\n</td>\n</tr>\n<tr style=\"height: 91.15pt;\">\n<td style=\"width: 154.75pt; border: solid #231F20 1.0pt; border-top: none; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm -1pt 0.0001pt 5.1pt; line-height: 12.65pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">H</span><span style=\"color: #231f20;\">aematological response</span><span style=\"font-size: 7.0pt; color: #231f20; position: relative; top: -5.0pt;\">1</span></p>\n<p style=\"margin: 0.3pt 25.7pt 0.0001pt 19.25pt; line-height: 102%; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">C</span><span style=\"color: #231f20;\">omplete haematological response (CHR)</span></p>\n<p style=\"margin: 0cm -1pt 0.0001pt 19.25pt; line-height: 12.65pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">N</span><span style=\"color: #231f20;\">o evidence of leukaemia</span></p>\n<p style=\"margin: 0.3pt -1pt 0.0001pt 19.25pt; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">(</span><span style=\"color: #231f20;\">N</span><span style=\"color: #231f20;\">EL)</span></p>\n<p style=\"margin: 0.3pt -1pt 0.0001pt 19.25pt; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">R</span><span style=\"color: #231f20;\">eturn to chronic phase</span></p>\n<p style=\"margin: 0.3pt -1pt 0.0001pt 19.25pt; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">(</span><span style=\"color: #231f20;\">R</span><span style=\"color: #231f20;\">T</span><span style=\"color: #231f20;\">C</span><span style=\"color: #231f20;\">)</span></p>\n</td>\n<td style=\"width: 94.75pt; border-top: none; border-left: none; border-bottom: solid #231F20 1.0pt; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 7pt 0.0001pt 7.95pt; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">95% (92.3&#8211;96.3)</span></p>\n<p style=\"margin: 0.3pt 34.1pt 0.0001pt 35.2pt; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">95%</span></p>\n<p style=\"margin: 0.3pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 13.0pt;\">&#160;</span></p>\n<p style=\"margin: 0cm 11.7pt 0.0001pt 12.75pt; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">N</span><span style=\"color: #231f20;\">ot applicable</span></p>\n<p style=\"margin: 0.25pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 13.0pt;\">&#160;</span></p>\n<p style=\"margin: 0cm 11.85pt 0.0001pt 12.85pt; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">N</span><span style=\"color: #231f20;\">ot applicable</span></p>\n</td>\n<td style=\"width: 99.3pt; border-top: none; border-left: none; border-bottom: solid #231F20 1.0pt; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 9.4pt 0.0001pt 10.1pt; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">71% (65.3&#8211;77.2)</span></p>\n<p style=\"margin: 0.3pt 36.5pt 0.0001pt 37.35pt; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">42%</span></p>\n<p style=\"margin: 0.3pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 13.0pt;\">&#160;</span></p>\n<p style=\"margin: 0cm 36.5pt 0.0001pt 37.35pt; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">12%</span></p>\n<p style=\"margin: 0.25pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 13.0pt;\">&#160;</span></p>\n<p style=\"margin: 0cm 36.5pt 0.0001pt 37.35pt; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">17%</span></p>\n</td>\n<td style=\"width: 96.35pt; border-top: none; border-left: none; border-bottom: solid #231F20 1.0pt; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 7.6pt 0.0001pt 8.65pt; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">31% (25.2&#8211;36.8)</span></p>\n<p style=\"margin: 0.3pt 37.7pt 0.0001pt 38.7pt; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">8%</span></p>\n<p style=\"margin: 0.3pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 13.0pt;\">&#160;</span></p>\n<p style=\"margin: 0cm 37.7pt 0.0001pt 38.7pt; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">5%</span></p>\n<p style=\"margin: 0.25pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 13.0pt;\">&#160;</span></p>\n<p style=\"margin: 0cm 34.95pt 0.0001pt 35.95pt; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">18%</span></p>\n</td>\n</tr>\n<tr style=\"height: 52.3pt;\">\n<td style=\"width: 154.75pt; border: solid #231F20 1.0pt; border-top: none; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm -1pt 0.0001pt 5.1pt; line-height: 12.65pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">Major cytogenetic response</span><span style=\"font-size: 7.0pt; color: #231f20; position: relative; top: -5.0pt;\">2</span></p>\n<p style=\"margin: 0.3pt -1pt 0.0001pt 19.25pt; line-height: 12.6pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">C</span><span style=\"color: #231f20;\">omplete</span></p>\n<p style=\"margin: 0.2pt 36pt 0.0001pt 19.25pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">(</span><span style=\"color: #231f20;\">C</span><span style=\"color: #231f20;\">onfirmed</span><span style=\"font-size: 7.0pt; color: #231f20; position: relative; top: -5.0pt;\">3</span><span style=\"color: #231f20;\">) [95% CI] Partial</span></p>\n</td>\n<td style=\"width: 94.75pt; border-top: none; border-left: none; border-bottom: solid #231F20 1.0pt; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 7pt 0.0001pt 7.95pt; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">65% (61.2&#8211;69.5)</span></p>\n<p style=\"margin: 0.3pt 34.1pt 0.0001pt 35.2pt; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">53%</span></p>\n<p style=\"margin: 0.3pt 3.3pt 0.0001pt 4.25pt; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">(</span><span style=\"color: #231f20;\">43%) [38.6&#8211;47.2]</span></p>\n<p style=\"margin: 0.3pt 34.1pt 0.0001pt 35.2pt; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">12%</span></p>\n</td>\n<td style=\"width: 99.3pt; border-top: none; border-left: none; border-bottom: solid #231F20 1.0pt; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 9.4pt 0.0001pt 10.1pt; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">28% (22.0&#8211;33.9)</span></p>\n<p style=\"margin: 0.3pt 36.5pt 0.0001pt 37.35pt; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">20%</span></p>\n<p style=\"margin: 0.3pt 5.7pt 0.0001pt 6.4pt; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">(</span><span style=\"color: #231f20;\">16%) [11.3&#8211;21.0]</span></p>\n<p style=\"margin: 0.3pt 39.25pt 0.0001pt 40.1pt; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">7%</span></p>\n</td>\n<td style=\"width: 96.35pt; border-top: none; border-left: none; border-bottom: solid #231F20 1.0pt; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 7.6pt 0.0001pt 8.65pt; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">15% (11.2&#8211;20.4)</span></p>\n<p style=\"margin: 0.3pt 37.7pt 0.0001pt 38.7pt; text-align: center; line-height: 12.6pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">7%</span></p>\n<p style=\"margin: 0.3pt 12.15pt 0.0001pt 13.2pt; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">(</span><span style=\"color: #231f20;\">2%) [0.6&#8211;4.4]</span></p>\n<p style=\"margin: 0.3pt 37.7pt 0.0001pt 38.7pt; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">8%</span></p>\n</td>\n</tr>\n<tr style=\"height: 196.7pt;\">\n<td style=\"width: 445.15pt; border: solid #231F20 1.0pt; border-top: none; padding: 0cm 0cm 0cm 0cm;\" colspan=\"4\" valign=\"top\">\n<p style=\"margin: 0cm -1pt 0.0001pt 5.1pt; line-height: 13.25pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"font-size: 7.0pt; color: #231f20; position: relative; top: -4.5pt;\">1 </span><span style=\"color: #231f20; position: relative; top: .5pt;\">H</span><span style=\"color: #231f20; position: relative; top: .5pt;\">aematological </span><span style=\"color: #231f20; position: relative; top: .5pt;\">r</span><span style=\"color: #231f20; position: relative; top: .5pt;\">e</span><span style=\"color: #231f20; position: relative; top: .5pt;\">sponse criteria (all responses to be confirmed after </span></strong><strong>&#8805;<span style=\"color: #231f20; position: relative; top: .5pt;\"> </span><span style=\"color: #231f20; position: relative; top: .5pt;\">4 weeks):</span></strong></p>\n<p style=\"margin: 0.05pt 13.1pt 0.0001pt 33.4pt; text-indent: -28.3pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">CHR</span><span style=\"color: #231f20;\">: Study 0110 [WBC &lt; 10 x 10</span><span style=\"font-size: 7.0pt; color: #231f20; position: relative; top: -5.0pt;\">9</span><span style=\"color: #231f20;\">/l</span><span style=\"color: #231f20;\">, platelets &lt; 450 x 10</span><span style=\"font-size: 7.0pt; color: #231f20; position: relative; top: -5.0pt;\">9</span><span style=\"color: #231f20;\">/l</span><span style=\"color: #231f20;\">, myelocyte+metamyelocyte &lt; 5% in blood, no blasts and promyelocytes in blood, basophils &lt; 20%, no extramedullary</span></p>\n<p style=\"margin: 0.7pt 18.15pt 0.0001pt 33.4pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">i</span><span style=\"color: #231f20;\">nvolvement] and in studies 0102 and 0109 [ANC </span><strong>&#8805;</strong><span style=\"color: #231f20;\"> </span><span style=\"color: #231f20;\">1.5 x 10</span><span style=\"font-size: 7.0pt; color: #231f20; position: relative; top: -5.0pt;\">9</span><span style=\"color: #231f20;\">/l</span><span style=\"color: #231f20;\">, platelets </span><strong>&#8805;</strong><span style=\"color: #231f20;\"> </span><span style=\"color: #231f20;\">100 x 10</span><span style=\"font-size: 7.0pt; color: #231f20; position: relative; top: -5.0pt;\">9</span><span style=\"color: #231f20;\">/l</span><span style=\"color: #231f20;\">, no blood blasts, BM blasts &lt; 5% and no extramedullary disease]</span></p>\n<p style=\"margin: 0.65pt 26.35pt 0.0001pt 33.4pt; text-indent: -28.3pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">N</span><span style=\"color: #231f20;\">EL &#160;Same criteria as for CHR but ANC </span><strong>&#8805;</strong><span style=\"color: #231f20;\"> </span><span style=\"color: #231f20;\">1 x 10</span><span style=\"font-size: 7.0pt; color: #231f20; position: relative; top: -5.0pt;\">9</span><span style=\"color: #231f20;\">/</span><span style=\"color: #231f20;\">l and platelets </span><strong>&#8805;</strong><span style=\"color: #231f20;\"> </span><span style=\"color: #231f20;\">20 x 10</span><span style=\"font-size: 7.0pt; color: #231f20; position: relative; top: -5.0pt;\">9</span><span style=\"color: #231f20;\">/</span><span style=\"color: #231f20;\">l (0102 and 0109 only)</span></p>\n<p style=\"margin: 0.05pt -1pt 0.0001pt 5.1pt; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">R</span><span style=\"color: #231f20;\">T</span><span style=\"color: #231f20;\">C &#160;&lt; 15% blasts BM and PB, &lt; 30% blasts+promyelocytes in BM and PB, &lt; 20% basophils in</span></p>\n<p style=\"margin: 0.3pt 43.95pt 0.0001pt 5.1pt; text-indent: 28.3pt; line-height: 102%; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">PB, no extramedullary disease other than spleen and liver (only for 0102 and 0109). BM = bone marrow, PB = peripheral blood</span></p>\n<p style=\"margin: 0cm -1pt 0.0001pt 5.1pt; line-height: 12.9pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"font-size: 7.0pt; color: #231f20; position: relative; top: -5.0pt;\">2 </span><span style=\"color: #231f20;\">C</span><span style=\"color: #231f20;\">ytogenetic response criteria:</span></strong></p>\n<p style=\"margin: 0.05pt 10.95pt 0.0001pt 5.1pt; line-height: 102%; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">A major response combines both complete and partial responses: complete (0% Ph+ metaphases), partial (1&#8211;35%)</span></p>\n<p style=\"margin: 0cm -1pt 0.0001pt 5.1pt; line-height: 12.65pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 7.0pt; color: #231f20; position: relative; top: -5.0pt;\">3 </span><span style=\"color: #231f20;\">C</span><span style=\"color: #231f20;\">omplete cytogenetic response confirmed by a second bone marrow cytogenetic evaluation</span></p>\n<p style=\"margin: 0.3pt -1pt 0.0001pt 5.1pt; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">performed at least one month after the initial bone marrow study.</span></p>\n</td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><em>Paediatric population</em></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">A total of 26 paediatric patients of age&#160;&lt;&#160;18 years with either chronic phase CML (n=11) or CML in blast crisis or Ph+ acute leukaemias (n=15) were enrolled in a dose‑escalation phase I trial. This was a population of heavily pretreated patients, as 46% had received prior BMT and 73% a prior multi‑agent chemotherapy. Patients were treated at doses of imatinib of 260&#160;mg/m<sup>2</sup>/day (n=5), 340&#160;mg/m<sup>2</sup>/day (n=9), 440&#160;mg/m<sup>2</sup>/day (n=7) and 570&#160;mg/m<sup>2</sup>/day (n=5). Out of 9 patients with chronic phase CML and cytogenetic data available, 4&#160;(44%) and 3&#160;(33%) achieved a complete and partial cytogenetic response, respectively, for a rate of MCyR of 77%.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">A total of 51 paediatric patients with newly diagnosed and untreated CML in chronic phase have been enrolled in an open‑label, multicentre, single‑arm phase II trial. Patients were treated with imatinib 340&#160;mg/m<sup>2</sup>/day, with no interruptions in the absence of dose limiting toxicity. Imatinib treatment induces a rapid response in newly diagnosed paediatric CML patients with a CHR of 78% after 8&#160;weeks of therapy. The high rate of CHR is accompanied by the development of a complete cytogenetic response (CCyR) of 65% which is comparable to the results observed in adults. Additionally, partial cytogenetic response (PCyR) was observed in 16% for a MCyR of 81%. The majority of patients who achieved a CCyR developed the CCyR between months 3 and 10 with a median time to response based on the Kaplan‑Meier estimate of 5.6&#160;months.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">The European Medicines Agency has waived the obligation to submit the results of studies with imatinib in all subsets of the paediatric population in Philadelphia chromosome (bcr‑abl translocation)-positive chronic myeloid leukaemia (see section 4.2 for information on paediatric use).</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt; color: black;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u><span style=\"color: black;\">Clinical studies in Ph+ ALL</span></u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u><span style=\"color: black;\">&#160;</span></u></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><em><span style=\"font-size: 11.0pt; color: black;\">Newly diagnosed Ph+ ALL</span></em></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt; color: black;\">In a controlled study (ADE10) of imatinib versus chemotherapy induction in 55 newly diagnosed patients aged 55 years and over, imatinib used as single agent induced a significantly higher rate of complete haematological response than chemotherapy (96.3% vs. 50%; p=0.0001). When salvage therapy with imatinib was administered in patients who did not respond or who responded poorly to chemotherapy, it resulted in 9 patients (81.8%) out of 11 achieving a complete haematological response. This clinical effect was associated with a higher reduction in bcr‑abl transcripts in the imatinib-treated patients than in the chemotherapy arm after 2 weeks of therapy (p=0.02). All patients received imatinib and consolidation chemotherapy (see Table 4) after induction and the levels of bcr‑abl transcripts were identical in the two arms at 8 weeks. As expected on the basis of the study design, no difference was observed in remission duration, disease‑free survival or overall survival, although patients with complete molecular response and remaining in minimal residual disease had a better outcome in terms of both remission duration (p=0.01) and disease-free survival (p=0.02).</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt; color: black;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">The results observed in a population of 211 newly diagnosed Ph+ ALL patients in four uncontrolled clinical studies (AAU02, ADE04, AJP01 and AUS01) are consistent with the results described above. Imatinib in combination with chemotherapy induction (see Table 4) resulted in a complete haematological response rate of 93% (147 out of 158 evaluable patients) and in a major cytogenetic response rate of 90% (19 out of 21 evaluable patients). The complete molecular response rate was 48% (49 out of 102 evaluable patients). Disease‑free survival (DFS) and overall survival (OS) constantly exceeded 1 year and were superior to historical control (DFS p&lt;0.001; OS p&lt;0.0001) in two studies (AJP01 and AUS01). </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"font-size: 11.0pt; color: black;\">Table 4&#160;&#160;&#160;&#160; Chemotherapy regimen used in combination with imatinib</span></strong></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt; color: black;\">&#160;</span></p>\n<div align=\"center\">&#160;</div>\n<table class=\"MsoNormalTable\" style=\"border-collapse: collapse; border: none; width: 98.2222%;\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td style=\"width: 100%; border: 1pt solid windowtext; padding: 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: black;\">Study ADE10</span></strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 47.2%; border-right: 1pt solid windowtext; border-bottom: 1pt solid windowtext; border-left: 1pt solid windowtext; border-image: initial; border-top: none; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Prephase</span></p>\n</td>\n<td style=\"width: 52.8%; border-top: none; border-left: none; border-bottom: 1pt solid windowtext; border-right: 1pt solid windowtext; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">DEX 10&#160;mg/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">oral, days 1-5; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">CP 200&#160;mg/m</span><sup><span style=\"color: black;\">2 </span></sup><span style=\"color: black;\">i.v., days 3, 4, 5; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">MTX 12&#160;mg intrathecal, day 1 </span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 47.2%; border-right: 1pt solid windowtext; border-bottom: 1pt solid windowtext; border-left: 1pt solid windowtext; border-image: initial; border-top: none; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Remission induction</span></p>\n</td>\n<td style=\"width: 52.8%; border-top: none; border-left: none; border-bottom: 1pt solid windowtext; border-right: 1pt solid windowtext; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">DEX 10&#160;mg/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">oral, days 6-7, 13-16; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">VCR 1&#160;mg i.v., days 7, 14; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">IDA 8&#160;mg/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">i.v. (0.5 h), days 7, 8, 14, 15; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">CP&#160;500 mg/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">i.v.(1 h) day 1; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Ara‑C&#160;60&#160;mg/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">i.v., days 22-25, 29-32 </span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 47.2%; border-right: 1pt solid windowtext; border-bottom: 1pt solid windowtext; border-left: 1pt solid windowtext; border-image: initial; border-top: none; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Consolidation therapy I, III, V</span></p>\n</td>\n<td style=\"width: 52.8%; border-top: none; border-left: none; border-bottom: 1pt solid windowtext; border-right: 1pt solid windowtext; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">MTX 500&#160;mg/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">i.v. (24 h), days 1, 15; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">6‑MP&#160;25&#160;mg/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">oral, days 1-20 </span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 47.2%; border-right: 1pt solid windowtext; border-bottom: 1pt solid windowtext; border-left: 1pt solid windowtext; border-image: initial; border-top: none; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Consolidation therapy II, IV</span></p>\n</td>\n<td style=\"width: 52.8%; border-top: none; border-left: none; border-bottom: 1pt solid windowtext; border-right: 1pt solid windowtext; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Ara‑C 75&#160;mg/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">i.v. (1 h), days 1-5; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">VM26&#160;60&#160;mg/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">i.v. (1 h), days 1-5 </span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 100%; border-right: 1pt solid windowtext; border-bottom: 1pt solid windowtext; border-left: 1pt solid windowtext; border-image: initial; border-top: none; padding: 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: black;\">Study AAU02 </span></strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 47.2%; border-right: 1pt solid windowtext; border-bottom: 1pt solid windowtext; border-left: 1pt solid windowtext; border-image: initial; border-top: none; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Induction therapy (<em>de novo </em>Ph+ ALL)</span></p>\n</td>\n<td style=\"width: 52.8%; border-top: none; border-left: none; border-bottom: 1pt solid windowtext; border-right: 1pt solid windowtext; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Daunorubicin 30&#160;mg/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">i.v., days 1-3, 15-16; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">VCR&#160;2&#160;mg total dose i.v., days 1, 8, 15, 22; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">CP&#160;750&#160;mg/m</span><sup><span style=\"color: black;\">2 </span></sup><span style=\"color: black;\">i.v., days 1, 8; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Prednisone 60&#160;mg/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">oral, days 1-7, 15-21; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">IDA 9&#160;mg/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">oral, days 1-28; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">MTX 15&#160;mg intrathecal, days 1, 8, 15, 22; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Ara‑C&#160;40&#160;mg intrathecal, days 1, 8, 15, 22; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Methylprednisolone 40&#160;mg intrathecal, days 1, 8, 15, 22 </span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 47.2%; border-right: 1pt solid windowtext; border-bottom: 1pt solid windowtext; border-left: 1pt solid windowtext; border-image: initial; border-top: none; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Consolidation (<em>de novo </em>Ph+ ALL)</span></p>\n</td>\n<td style=\"width: 52.8%; border-top: none; border-left: none; border-bottom: 1pt solid windowtext; border-right: 1pt solid windowtext; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Ara-C 1,000&#160;mg/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"color: black;\">/12 h i.v.(3 h), days 1-4; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Mitoxantrone 10&#160;mg/m</span><sup><span style=\"color: black;\">2 </span></sup><span style=\"color: black;\">i.v. days 3-5; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">MTX 15&#160;mg intrathecal, day 1; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Methylprednisolone 40&#160;mg intrathecal, day 1 </span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 100%; border-right: 1pt solid windowtext; border-bottom: 1pt solid windowtext; border-left: 1pt solid windowtext; border-image: initial; border-top: none; padding: 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: black;\">Study ADE04</span></strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 47.2%; border-right: 1pt solid windowtext; border-bottom: 1pt solid windowtext; border-left: 1pt solid windowtext; border-image: initial; border-top: none; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Prephase</span></p>\n</td>\n<td style=\"width: 52.8%; border-top: none; border-left: none; border-bottom: 1pt solid windowtext; border-right: 1pt solid windowtext; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">DEX 10&#160;mg/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">oral, days 1-5; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">CP 200&#160;mg/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">i.v., days 3-5; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">MTX 15 mg intrathecal, day 1 </span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 47.2%; border-right: 1pt solid windowtext; border-bottom: 1pt solid windowtext; border-left: 1pt solid windowtext; border-image: initial; border-top: none; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Induction therapy I</span></p>\n</td>\n<td style=\"width: 52.8%; border-top: none; border-left: none; border-bottom: 1pt solid windowtext; border-right: 1pt solid windowtext; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">DEX 10&#160;mg/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">oral, days 1-5; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">VCR 2&#160;mg i.v., days 6, 13, 20; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Daunorubicin 45&#160;mg/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">i.v., days 6-7, 13-14 </span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 47.2%; border-right: 1pt solid windowtext; border-bottom: 1pt solid windowtext; border-left: 1pt solid windowtext; border-image: initial; border-top: none; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Induction therapy II</span></p>\n</td>\n<td style=\"width: 52.8%; border-top: none; border-left: none; border-bottom: 1pt solid windowtext; border-right: 1pt solid windowtext; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">CP 1&#160;g/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">i.v. (1 h), days 26, 46; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Ara‑C 75&#160;mg/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">i.v. (1 h), days 28-31, 35-38, 42-45; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">6-MP 60&#160;mg/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">oral, days 26-46 </span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 47.2%; border-right: 1pt solid windowtext; border-bottom: 1pt solid windowtext; border-left: 1pt solid windowtext; border-image: initial; border-top: none; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Consolidation therapy</span></p>\n</td>\n<td style=\"width: 52.8%; border-top: none; border-left: none; border-bottom: 1pt solid windowtext; border-right: 1pt solid windowtext; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">DEX 10&#160;mg/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">oral, days 1-5; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Vindesine 3&#160;mg/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">i.v., day 1; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">MTX 1.5&#160;g/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">i.v. (24 h), day 1; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Etoposide 250&#160;mg/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">i.v. (1 h) days 4-5; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Ara-C 2x 2&#160;g/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">i.v. (3 h, q 12 h), day 5 </span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 100%; border-right: 1pt solid windowtext; border-bottom: 1pt solid windowtext; border-left: 1pt solid windowtext; border-image: initial; border-top: none; padding: 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: black;\">Study AJP01</span></strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 47.2%; border-right: 1pt solid windowtext; border-bottom: 1pt solid windowtext; border-left: 1pt solid windowtext; border-image: initial; border-top: none; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Induction therapy</span></p>\n</td>\n<td style=\"width: 52.8%; border-top: none; border-left: none; border-bottom: 1pt solid windowtext; border-right: 1pt solid windowtext; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">CP 1.2&#160;g/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">i.v. (3 h), day 1; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Daunorubicin 60&#160;mg/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">i.v. (1 h), days 1-3; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Vincristine 1.3&#160;mg/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">i.v., days 1, 8, 15, 21; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Prednisolone 60&#160;mg/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"color: black;\">/day oral </span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 47.2%; border-right: 1pt solid windowtext; border-bottom: 1pt solid windowtext; border-left: 1pt solid windowtext; border-image: initial; border-top: none; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Consolidation therapy</span></p>\n</td>\n<td style=\"width: 52.8%; border-top: none; border-left: none; border-bottom: 1pt solid windowtext; border-right: 1pt solid windowtext; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Alternating chemotherapy course: high dose chemotherapy with MTX 1&#160;g/m</span><sup><span style=\"color: black;\">2 </span></sup><span style=\"color: black;\">i.v. (24 h), day 1, and Ara-C 2&#160;g/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">i.v. (q 12 h), days 2-3, for 4 cycles </span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 47.2%; border-right: 1pt solid windowtext; border-bottom: 1pt solid windowtext; border-left: 1pt solid windowtext; border-image: initial; border-top: none; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Maintenance</span></p>\n</td>\n<td style=\"width: 52.8%; border-top: none; border-left: none; border-bottom: 1pt solid windowtext; border-right: 1pt solid windowtext; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">VCR 1.3&#160;g/m</span><sup><span style=\"color: black;\">2</span></sup><span style=\"font-size: 7.0pt; color: black;\"> </span><span style=\"color: black;\">i.v., day 1; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Prednisolone 60&#160;mg/m</span><sup><span style=\"color: black;\">2 </span></sup><span style=\"color: black;\">oral, days 1-5 </span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 100%; border-right: 1pt solid windowtext; border-bottom: 1pt solid windowtext; border-left: 1pt solid windowtext; border-image: initial; border-top: none; padding: 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: black;\">Study AUS01</span></strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 47.2%; border-right: 1pt solid windowtext; border-bottom: 1pt solid windowtext; border-left: 1pt solid windowtext; border-image: initial; border-top: none; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Induction-consolidation therapy</span></p>\n</td>\n<td style=\"width: 52.8%; border-top: none; border-left: none; border-bottom: 1pt solid windowtext; border-right: 1pt solid windowtext; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Hyper-CVAD regimen: CP 300&#160;mg/m<sup>2</sup> i.v. (3 h, q&#160;12&#160;h), days 1-3; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Vincristine 2&#160;mg i.v., days 4, 11; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Doxorubicine 50&#160;mg/m<sup>2</sup> i.v. (24 h), day 4; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">DEX&#160;40&#160;mg/day on days 1-4 and 11-14, alternated with MTX 1&#160;g/m<sup>2</sup> i.v. (24 h), day 1, </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Ara-C 1&#160;g/m<sup>2</sup> i.v. (2 h, q 12 h), days 2-3 (total of 8 courses)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 47.2%; border-right: 1pt solid windowtext; border-bottom: 1pt solid windowtext; border-left: 1pt solid windowtext; border-image: initial; border-top: none; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Maintenance</span></p>\n</td>\n<td style=\"width: 52.8%; border-top: none; border-left: none; border-bottom: 1pt solid windowtext; border-right: 1pt solid windowtext; padding: 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">VCR 2&#160;mg i.v. monthly for 13 months; </span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Prednisolone 200&#160;mg oral, 5 days per month for 13 months</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 100%; border-right: 1pt solid windowtext; border-bottom: 1pt solid windowtext; border-left: 1pt solid windowtext; border-image: initial; border-top: none; padding: 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">All treatment regimens include administration of steroids for CNS prophylaxis.</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 100%; border-right: 1pt solid windowtext; border-bottom: 1pt solid windowtext; border-left: 1pt solid windowtext; border-image: initial; border-top: none; padding: 0cm 5.4pt;\" colspan=\"2\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Ara-C: cytosine arabinoside; CP: cyclophosphamide; DEX: dexamethasone; MTX: methotrexate; 6-MP: 6-mercaptopurine VM26: Teniposide; VCR: vincristine; IDA: idarubicine; i.v.: intravenous </span></p>\n</td>\n</tr>\n</tbody>\n</table>\n<div align=\"center\">&#160;</div>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt; color: black;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><em><span style=\"color: black;\">Paediatric population</span></em></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">In study I2301, a total of 93 paediatric, adolescent and young adult patients (from 1 to 22 years old) with Ph+ ALL were enrolled in an open-label, multicentre, sequential cohort, non‑randomized phase III trial, and were treated with imatinib (340 mg/m<sup>2</sup>/day) in combination with intensive chemotherapy after induction therapy. Imatinib was administered intermittently in cohorts 1‑5, with increasing duration and earlier start of imatinib from cohort to cohort; cohort 1 receiving the lowest intensitiy and cohort 5 receiving the highest intensity of imatinib (longest duration in days with continuous daily imatinib dosing during the first chemotherapy treatment courses). Continuous daily exposure to imatinib early in the course of treatment in combination with chemotherapy in cohort 5‑patients (n=50) improved the 4‑year event‑free survival (EFS) compared to historical controls (n=120), who received standard chemotherapy without imatinib (69.6% vs. 31.6%, respectively). The estimated 4‑year OS in cohort 5‑patients was 83.6% compared to 44.8% in the historical controls. 20 out of the 50 (40%) patients in cohort 5 received haematopoietic stem cell transplant.</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><em><span style=\"color: black;\">&#160;</span></em></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: black;\">Table 5&#160;&#160;&#160;&#160; Chemotherapy regimen used in combination with imatinib in study I2301</span></strong></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><em><span style=\"color: black;\">&#160;</span></em></p>\n<table class=\"MsoNormalTable\" style=\"border-collapse: collapse; border: none;\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td style=\"width: 125.25pt; border: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Consolidation block 1</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">(3 weeks)</span></p>\n</td>\n<td style=\"width: 328.05pt; border: solid windowtext 1.0pt; border-left: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">VP-16 (100 mg/m<sup>2</sup>/day, IV): days 1-5</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Ifosfamide (1.8 g/m<sup>2</sup>/day, IV): days 1-5</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">MESNA (360 mg/m<sup>2</sup>/dose q3h, x 8 doses/day, IV): days 1-5</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">G-CSF (5 &#956;g/kg, SC): days 6-15 or until ANC &gt; 1500 post nadir</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">IT Methotrexate (age-adjusted): day 1 ONLY</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Triple IT therapy (age-adjusted): day 8, 15</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.25pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Consolidation block 2</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">(3 weeks)</span></p>\n</td>\n<td style=\"width: 328.05pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Methotrexate (5 g/m<sup>2</sup> over 24 hours, IV): day 1</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Leucovorin (75 mg/m<sup>2</sup> at hour 36, IV; 15 mg/m<sup>2</sup> IV or PO q6h x 6 doses)iii:</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Days 2 and 3</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Triple IT therapy (age-adjusted): day 1</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">ARA-C (3 g/m<sup>2</sup>/dose q 12 h x 4, IV): days 2 and 3</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">G-CSF (5 &#956;g/kg, SC): days 4-13 or until ANC &gt; 1500 post nadir</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.25pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Reinduction block 1</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">(3 weeks)</span></p>\n</td>\n<td style=\"width: 328.05pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">VCR (1.5 mg/m<sup>2</sup>/day, IV): days 1, 8, and 15</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">DAUN (45 mg/m<sup>2</sup>/day bolus, IV): days 1 and 2</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">CPM (250 mg/m<sup>2</sup>/dose q12h x 4 doses, IV): days 3 and 4</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">PEG-ASP (2500 IUnits/m<sup>2</sup>, IM): day 4</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">G-CSF (5 &#956;g/kg, SC): days 5-14 or until ANC &gt; 1500 post nadir</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Triple IT therapy (age-adjusted): days 1 and 15</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">DEX (6 mg/m<sup>2</sup>/day, PO): days 1-7 and 15-21</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.25pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Intensification block 1</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">(9 weeks)</span></p>\n</td>\n<td style=\"width: 328.05pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Methotrexate (5 g/m<sup>2</sup> over 24 hours, IV): days 1 and 15</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Leucovorin (75 mg/m<sup>2</sup> at hour 36, IV; 15 mg/m<sup>2</sup> IV or PO q6h x 6 doses)iii: days 2, 3, 16, and 17</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Triple IT therapy (age-adjusted): days 1 and 22</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">VP-16 (100 mg/m<sup>2</sup>/day, IV): days 22-26</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">CPM (300 mg/m<sup>2</sup>/day, IV): days 22-26</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">MESNA (150 mg/m<sup>2</sup>/day, IV): days 22-26</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">G-CSF (5 &#956;g/kg, SC): days 27-36 or until ANC &gt; 1500 post nadir</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">ARA-C (3 g/m<sup>2</sup>, q12h, IV): days 43, 44</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">L-ASP (6000 IUnits/m<sup>2</sup>, IM): day 44</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.25pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Reinduction block 2</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">(3 weeks)</span></p>\n</td>\n<td style=\"width: 328.05pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">VCR (1.5 mg/m<sup>2</sup>/day, IV): days 1, 8 and 15</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">DAUN (45 mg/m<sup>2</sup>/day bolus, IV): days 1 and 2</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">CPM (250 mg/m<sup>2</sup>/dose q12h x 4 doses, iv): Days 3 and 4</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">PEG-ASP (2500 IUnits/m<sup>2</sup>, IM): day 4</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">G-CSF (5 &#956;g/kg, SC): days 5-14 or until ANC &gt; 1500 post nadir</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Triple IT therapy (age-adjusted): days 1 and 15</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">DEX (6 mg/m<sup>2</sup>/day, PO): days 1-7 and 15-21</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.25pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Intensification block 2</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">(9 weeks)</span></p>\n</td>\n<td style=\"width: 328.05pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Methotrexate (5 g/m<sup>2</sup> over 24 hours, IV): days 1 and 15</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Leucovorin (75 mg/m<sup>2</sup> at hour 36, IV; 15 mg/m<sup>2</sup> IV or PO q6h x 6 doses)iii: days 2, 3, 16, and 17</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Triple IT therapy (age-adjusted): days 1 and 22</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">VP-16 (100 mg/m<sup>2</sup>/day, IV): days 22-26</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">CPM (300 mg/m<sup>2</sup>/day, IV): days 22-26</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">MESNA (150 mg/m<sup>2</sup>/day, IV): days 22-26</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">G-CSF (5 &#956;g/kg, SC): days 27-36 or until ANC &gt; 1500 post nadir</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">ARA-C (3 g/m<sup>2</sup>, q12h, IV): days 43, 44</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">L-ASP (6000 IUnits/m<sup>2</sup>, IM): day 44</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.25pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Maintenance</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">(8-week cycles)</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Cycles 1&#8211;4</span></p>\n</td>\n<td style=\"width: 328.05pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">MTX (5 g/m<sup>2</sup> over 24 hours, IV): day 1</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Leucovorin (75 mg/m<sup>2</sup> at hour 36, IV; 15 mg/m<sup>2</sup> IV or PO q6h x 6 doses)iii: days 2 and 3</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Triple IT therapy (age-adjusted): days 1, 29</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">VCR (1.5 mg/m<sup>2</sup>, IV): days 1, 29</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">DEX (6 mg/m<sup>2</sup>/day PO): days 1-5; 29-33</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">6-MP (75 mg/m<sup>2</sup>/day, PO): days 8-28</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Methotrexate (20 mg/m<sup>2</sup>/week, PO): days 8, 15, 22</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">VP-16 (100 mg/m<sup>2</sup>, IV): days 29-33</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">CPM (300 mg/m<sup>2</sup>, IV): days 29-33</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">MESNA IV days 29-33</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">G-CSF (5 &#956;g/kg, SC): days 34-43</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.25pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Maintenance</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">(8-week cycles)</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Cycle 5</span></p>\n</td>\n<td style=\"width: 328.05pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Cranial irradiation (Block 5 only)</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">12 Gy in 8 fractions for all patients that are CNS1 and CNS2 at diagnosis</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">18 Gy in 10 fractions for patients that are CNS3 at diagnosis</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">VCR (1.5 mg/m<sup>2</sup>/day, IV): days 1, 29</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">DEX (6 mg/m<sup>2</sup>/day, PO): days 1-5; 29-33</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">6-MP (75 mg/m<sup>2</sup>/day, PO): days 11-56 (Withhold 6-MP during the 6-10 days of cranial irradiation beginning on day 1 of Cycle 5. Start 6-MP the 1st day after cranial irradiation completion.)</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Methotrexate (20 mg/m<sup>2</sup>/week, PO): days 8, 15, 22, 29, 36, 43, 50</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 125.25pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Maintenance</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">(8-week cycles)</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Cycles 6-12</span></p>\n</td>\n<td style=\"width: 328.05pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">VCR (1.5 mg/m<sup>2</sup>/day, IV): days 1, 29</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">DEX (6 mg/m<sup>2</sup>/day, PO): days 1-5; 29-33</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">6-MP (75 mg/m<sup>2</sup>/day, PO): days 1-56</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Methotrexate (20 mg/m<sup>2</sup>/week, PO): days 1, 8, 15, 22, 29, 36, 43, 50</span></p>\n</td>\n</tr>\n</tbody>\n</table>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">G-CSF = granulocyte colony stimulating factor, VP-16 = etoposide, MTX = methotrexate, IV = intravenous, SC = subcutaneous, IT = intrathecal, PO = oral, IM = intramuscular, ARA-C = cytarabine, CPM = cyclophosphamide, VCR = vincristine, DEX = dexamethasone, DAUN = daunorubicin, 6-MP = 6-mercaptopurine, E.Coli L-ASP = L-asparaginase, PEG-ASP = PEG asparaginase, MESNA= 2-mercaptoethane sulfonate sodium, iii= or until MTX level is &lt; 0.1 &#956;M, q6h = every 6 hours, Gy= Gray</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt; color: black;\">Study AIT07 was a multicentre, open-label, randomised, phase II/III study that included 128 patients (1 to &lt; 18 years) treated with imatinib in combination with chemotherapy. Safety data from this study seem to be in line with the safety profile of imatinib in Ph+ ALL patients.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt; color: black;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><em><span style=\"color: black;\">Relapsed/refractory Ph+ ALL</span></em></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">When imatinib was used as single agent in patients with relapsed/refractory Ph+ ALL, it resulted, in the 53 out of 411 patients evaluable for response, in a haematological response rate of 30% (9% complete) and a major cytogenetic response rate of 23%. (Of note, out of the 411 patients, 353 were treated in an expanded access program without primary response data collected.) The median time to progression in the overall population of 411 patients with relapsed/refractory Ph+ ALL ranged from 2.6 to 3.1 months, and median overall survival in the 401 evaluable patients ranged from 4.9 to 9 months. The data was similar when re-analysed to include only those patients age 55 or older.</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u><span style=\"color: black;\">Clinical studies in MDS/MPD</span></u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Experience with imatinib in this indication is very limited and is based on haematological and cytogenetic response rates. There are no controlled trials demonstrating a clinical benefit or increased survival. One open label, multicentre, phase II clinical trial (study B2225) was conducted testing imatinib in diverse populations of patients suffering from life-threatening diseases associated with Abl, Kit or PDGFR protein tyrosine kinases. This study included 7 patients with MDS/MPD who were treated with imatinib 400&#160;mg daily. Three patients presented a complete haematological response (CHR) and one patient experienced a partial haematological response (PHR). At the time of the original analysis, three of the four patients with detected PDGFR gene rearrangements developed haematological response (2 CHR and 1 PHR). The age of these patients ranged from 20 to 72&#160;years.</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">An observational registry (study L2401) was conducted to collect </span>long-term safety and efficacy data in patients suffering from <span style=\"color: black;\">myeloproliferative </span>neoplasms with PDGFR- &#946; rearrangement and who were treated with imatinib.<span style=\"color: black;\"> The 23&#160;patients enrolled in this registry received imatinib at a median daily dose of 264&#160;mg (range: 100 to 400&#160;mg) for a median duration of 7.2&#160;years (range 0.1 to 12.7&#160;years). </span>Due to the observational nature of this registry, haematologic, cytogenetic and molecular assessment <span style=\"color: black;\">data were available for 22, 9 and 17 of the 23&#160;enrolled patients, respectively. When assuming conservatively that patients with missing data were non-responders, CHR was observed in 20/23 (87%) patients, CCyR in 9/23 (39.1%) patients, and MR in 11/23 (47.8%) patients, respectively. When the response rate is calculated from patients with at least one valid assessment, the response rate for CHR, CCyR and MR was 20/22 (90.9%), 9/9 (100%) and 11/17 (64.7%), respectively.</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">In addition a further 24 patients with MDS/MPD were reported in 13 publications. 21 patients were treated with imatinib 400&#160;mg daily, while the other 3 patients received lower doses. In eleven patients PDGFR gene rearrangements was detected, 9 of them achieved a CHR and 1 PHR. The age of these patients ranged from 2 to 79 years. In a recent publication updated information from 6 of these 11 patients revealed that all these patients remained in cytogenetic remission (range 32-38 months). The same publication reported long term follow-up data from 12 MDS/MPD patients with PDGFR gene rearrangements (5 patients from study B2225). These patients received imatinib for a median of 47 months (range 24 days &#8211; 60 months). In 6 of these patients follow-up now exceeds 4 years. Eleven patients achieved rapid CHR; ten had complete resolution of cytogenetic abnormalities and a decrease or disappearance of fusion transcripts as measured by RT-PCR. Haematological and cytogenetic responses have been sustained for a median of 49 months (range 19-60) and 47 months (range 16-59), respectively. The overall survival is 65 months since diagnosis (range 25-234). Imatinib administration to patients without the genetic translocation generally results in no improvement.</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">There are no controlled trials in paediatric patients with MDS/MPD. Five (5)&#160;patients with MDS/MPD associated with PDGFR gene re-arrangements were reported in 4&#160;publications. The age of these patients ranged from 3&#160;months to 4&#160;years and imatinib was given at dose 50&#160;mg daily or doses ranging from 92.5 to 340&#160;mg/m<sup>2</sup> daily. All patients achieved complete haematological response, cytogenetic response and/or clinical response.</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u><span style=\"color: black;\">Clinical studies in HES/CEL</span></u></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt; color: black;\">One open-label, multicentre, phase II clinical trial (study B2225) was conducted testing imatinib in diverse populations of patients suffering from life-threatening diseases associated with Abl, Kit or PDGFR protein tyrosine kinases. In this study, 14 patients with HES/CEL were treated with 100&#160;mg to 1,000&#160;mg of imatinib daily. A further 162 patients with HES/CEL, reported in 35 published case reports and case series received imatinib at doses from 75&#160;mg to 800&#160;mg daily. Cytogenetic abnormalities were evaluated in 117 of the total population of 176 patients. In 61 of these 117 patients </span><span style=\"font-size: 11.0pt;\">FIP1L1-PDGFR&#945; fusion kinase was identified. An additional four HES patients were found to be FIP1L1-PDGFR&#945;-positive in other 3 published reports. All 65 FIP1L1-PDGFR&#945; fusion kinase positive patients achieved a CHR sustained for months (range from 1+ to 44+ months censored at the time of the reporting). As reported in a recent publication 21 of these 65 patients also achieved complete molecular remission with a median follow-up of 28 months (range 13-67 months). The age of these patients ranged from 25 to 72 years. Additionally, improvements in symptomatology and other organ dysfunction abnormalities were reported by the investigators in the case reports. Improvements were reported in cardiac, nervous, skin/subcutaneous tissue, respiratory/thoracic/mediastinal, musculoskeletal/connective tissue/vascular, and gastrointestinal organ systems.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; text-align: left; font-size: 12pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt; color: black;\">There are no controlled trials in paediatric patients with HES/CEL. Three (3)&#160;patients with HES and CEL associated with PDGFR gene re-arrangements were reported in 3&#160;publications. The age of these patients ranged from 2 to 16&#160;years and imatinib was given at dose 300&#160;mg/m<sup>2</sup> daily or doses ranging from 200 to 400&#160;mg daily. All patients achieved complete haematological response, complete cytogenetic response and/or complete molecular response.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u><span style=\"color: black;\">Clinical studies in unresectable and/or metastatic GIST</span></u></p>\n<p style=\"margin: 0.05pt -0.05pt 0.0001pt 0cm; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">One phase II, open-label, randomised, uncontrolled multinational study was conducted in patients with unresectable or metastatic malignant gastrointestinal stromal tumours (GIST). In this study</span></p>\n<p style=\"margin: 0cm -0.05pt 0.0001pt 0cm; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">147 patients were enrolled and randomised to receive either 400 mg or 600 mg orally once daily for up to 36 months. These patients ranged in age from 18 to 83 years old and had a pathologic diagnosis of Kit-positive malignant GIST that was unresectable and/or metastatic. Immunohistochemistry was routinely performed with Kit antibody (A-4502, rabbit polyclonal antiserum, 1:100; DAKO Corporation, Carpinteria, CA) according to analysis by an avidin-biotin-peroxidase complex method after antigen retrieval.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"margin: 0cm -0.05pt 0.0001pt 0cm; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">The primary evidence of efficacy was based on objective response rates. Tumours were required to be measurable in at least one site of disease, and response characterisation based on Southwestern Oncology Group (SWOG) criteria. Results are provided in Table 6.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: black;\">Table 6&#160;&#160;&#160;&#160; Best tumour response in trial STIB2222 (GIST)</span></strong></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<table class=\"MsoTableGrid\" style=\"border-collapse: collapse; border: none;\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td style=\"width: 226.5pt; border-top: solid windowtext 1.0pt; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">Best response</span></p>\n</td>\n<td style=\"width: 226.55pt; border-top: solid windowtext 1.0pt; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt -1pt; text-align: center; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">All doses (n=147)</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt 1.65pt; text-align: center; text-indent: 0.4pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">400 mg (n=73)</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt 1.65pt; text-align: center; text-indent: 0.4pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">600 mg (n=74)</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt 1.65pt; text-align: center; text-indent: 0.4pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">n (%)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 226.5pt; border: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">Complete response</span></p>\n</td>\n<td style=\"width: 226.55pt; border: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"text-align: center; margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">1 (0.7)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 226.5pt; border: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">Partial response</span></p>\n</td>\n<td style=\"width: 226.55pt; border: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"text-align: center; margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">98 (66.7)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 226.5pt; border: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">Stable disease</span></p>\n</td>\n<td style=\"width: 226.55pt; border: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"text-align: center; margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">23 (15.6)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 226.5pt; border: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">Progressive disease</span></p>\n</td>\n<td style=\"width: 226.55pt; border: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"text-align: center; margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">18 (12.2)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 226.5pt; border: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">Not evaluable</span></p>\n</td>\n<td style=\"width: 226.55pt; border: none; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"text-align: center; margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">5 (3.4)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 226.5pt; border: none; border-bottom: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">Unknown</span></p>\n</td>\n<td style=\"width: 226.55pt; border: none; border-bottom: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\" valign=\"top\">\n<p style=\"text-align: center; margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">2 (1.4)</span></p>\n</td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"margin: 0cm -0.05pt 0.0001pt 0cm; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">There were no differences in response rates between the two dose groups. A significant number of patients who had stable disease at the time of the interim analysis achieved a partial response with longer treatment (median follow-up 31 months). Median time to response was 13 weeks (95% C.I. 12&#8211;23). Median time to treatment failure in responders was 122 weeks (95% C.I 106&#8211;147), while in the overall study population it was 84 weeks (95% C.I 71&#8211;109). The median overall survival has not been reached. The Kaplan-Meier estimate for survival after 36-month follow-up is 68%.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"margin: 0cm -0.05pt 0.0001pt 0cm; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">In two clinical studies (study B2222 and an intergroup study S0033) the daily dose of </span><span style=\"color: black;\">imatinib</span><span style=\"color: black;\"> was escalated to 800 mg in patients progressing at the lower daily doses of 400 mg or 600 mg. The daily dose was escalated to 800 mg in a total of 103 patients; 6 patients achieved a partial response and 21 stabilisation of their disease after dose escalation for an overall clinical benefit of 26%. From the safety data available, escalating the dose to 800 mg daily in patients progressing at lower doses of 400 mg or 600 mg daily does not seem to affect the safety profile of </span><span style=\"color: black;\">imatinib</span><span style=\"color: black;\">.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u><span style=\"color: black;\">Clinical studies in adjuvant GIST</span></u></p>\n<p style=\"margin: 0cm -0.05pt 0.0001pt 0cm; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">In the adjuvant setting, </span><span style=\"color: black;\">imatinib</span><span style=\"color: black;\"> was investigated in a multicentre, double-blind, long-term, placebo- controlled phase III study (Z9001) involving 773 patients. The ages of these patients ranged from 18 to 91 years. Patients were included who had a histological diagnosis of primary GIST expressing Kit protein by immunochemistry and a tumour size &#8805; 3 cm in maximum dimension, with complete gross resection of primary GIST within 14-70 days prior to registration. After resection of primary GIST, patients were randomised to one of the two arms: </span><span style=\"color: black;\">imatinib</span><span style=\"color: black;\"> at 400 mg/day or matching placebo for one year.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"margin: 0.05pt -0.05pt 0.0001pt 0cm; font-size: 11pt; font-family: 'Times New Roman', serif; color: green; font-style: italic;\"><span style=\"color: black; font-style: normal;\">The primary endpoint of the study was recurrence-free survival (RFS), defined as the time from date of randomisation to the date of recurrence or death from any cause.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"margin: 0.05pt -0.05pt 0.0001pt 0cm; font-size: 11pt; font-family: 'Times New Roman', serif; color: green; font-style: italic;\"><span style=\"color: black; font-style: normal;\">Imatinib significantly prolonged RFS, with 75% of patients being recurrence-free at 38 months in the imatinib group vs. 20 months in the placebo group (95% CIs, [30 - non-estimable]; [14 - non-estimable], respectively); (hazard ratio = 0.398 [0.259-0.610], p&lt;0.0001). At one year the overall RFS was significantly better for imatinib (97.7%) vs. placebo (82.3%), (p&lt;0.0001). The risk of recurrence was thus reduced by approximately 89% as compared with placebo (hazard ratio = 0.113 [0.049-0.264]).</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"margin: 0cm -0.05pt 0.0001pt 0cm; font-size: 11pt; font-family: 'Times New Roman', serif; color: green; font-style: italic;\"><span style=\"color: black; font-style: normal;\">The risk of recurrence in patients after surgery of their primary GIST was retrospectively assessed based on the following prognostic factors: tumour size, mitotic index, tumour location. Mitotic index data were available for 556 of the 713 intention-to-treat (ITT) population. The results of subgroup analyses according to the United States National Institutes of Health (NIH) and the Armed Forces Institute of Pathology (AFIP) risk classifications are shown in Table 7. No benefit was observed in the low and very low risk groups. No overall survival benefit has been observed.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: black;\">Table 7&#160;&#160;&#160;&#160; Summary of Z9001 trial RFS analyses by NIH and AFIP risk classifications</span></strong></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<table class=\"MsoNormalTable\" style=\"width: 0px; border-collapse: collapse; border: none;\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr style=\"height: 12.65pt;\">\n<td style=\"width: 46.65pt; border: solid #231F20 1.0pt; border-bottom: solid black 1.0pt; padding: 0cm 0cm 0cm 0cm;\" rowspan=\"3\" valign=\"top\">\n<p style=\"margin: 0cm 4.45pt 0.0001pt 5.85pt; text-indent: 6.7pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: #231f20;\">Risk criteria</span></strong></p>\n</td>\n<td style=\"width: 70.9pt; border-top: solid #231F20 1.0pt; border-left: none; border-bottom: solid black 1.0pt; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" rowspan=\"3\" valign=\"top\">\n<p style=\"line-height: 12.55pt; margin: 0cm 0cm 0.0001pt 5.35pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: #231f20;\">Risk Level</span></strong></p>\n</td>\n<td style=\"width: 49.35pt; border-top: solid #231F20 1.0pt; border-left: none; border-bottom: solid black 1.0pt; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" rowspan=\"3\" valign=\"top\">\n<p style=\"margin: 0cm 4.7pt 0.0001pt 5.85pt; text-indent: 7.05pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: #231f20;\">% of patients</span></strong></p>\n</td>\n<td style=\"width: 104.05pt; border: solid #231F20 1.0pt; border-left: none; padding: 0cm 0cm 0cm 0cm;\" rowspan=\"2\" valign=\"top\">\n<p style=\"margin: 0cm 16.6pt 0.0001pt 17.8pt; text-indent: 1.05pt; line-height: 12.7pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: #231f20;\">No. of events / No. of patients</span></strong></p>\n</td>\n<td style=\"width: 90.0pt; border-top: solid #231F20 1.0pt; border-left: none; border-bottom: solid black 1.0pt; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" rowspan=\"3\" valign=\"top\">\n<p style=\"margin: 0cm 7.4pt 0.0001pt 8.65pt; text-indent: 0.6pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: #231f20;\">Overall hazard ratio (95%CI)*</span></strong></p>\n</td>\n<td style=\"width: 140.15pt; border: solid #231F20 1.0pt; border-left: none; padding: 0cm 0cm 0cm 0cm;\" colspan=\"2\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 35.95pt; line-height: 11.7pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: #231f20;\">RFS rates (%)</span></strong></p>\n</td>\n</tr>\n<tr style=\"height: 12.55pt;\">\n<td style=\"width: 72.05pt; border-top: none; border-left: none; border-bottom: solid #231F20 1.0pt; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 13.65pt; line-height: 11.55pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: #231f20;\">12 month</span></strong></p>\n</td>\n<td style=\"width: 68.1pt; border-top: none; border-left: none; border-bottom: solid #231F20 1.0pt; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 4.15pt 0.0001pt 4.25pt; text-align: center; line-height: 11.55pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: #231f20;\">24 month</span></strong></p>\n</td>\n</tr>\n<tr style=\"height: 25.25pt;\">\n<td style=\"width: 104.05pt; border-top: none; border-left: none; border-bottom: solid black 1.0pt; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 11.2pt; line-height: 12.55pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: black;\">imatinib</span></strong><strong><span style=\"color: #231f20;\"> vs placebo</span></strong></p>\n</td>\n<td style=\"width: 72.05pt; border-top: none; border-left: none; border-bottom: solid black 1.0pt; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 13.6pt 0.0001pt 7.3pt; line-height: 12.7pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: black;\">imatinib</span></strong><strong><span style=\"color: #231f20;\"> vs placebo</span></strong></p>\n</td>\n<td style=\"width: 68.1pt; border-top: none; border-left: none; border-bottom: solid black 1.0pt; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 11.6pt 0.0001pt 6.2pt; line-height: 12.7pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: black;\">imatinib</span></strong><strong><span style=\"color: #231f20;\"> vs placebo</span></strong></p>\n</td>\n</tr>\n<tr style=\"height: 12.7pt;\">\n<td style=\"width: 46.65pt; border-top: none; border-left: solid #231F20 1.0pt; border-bottom: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"line-height: 11.7pt; margin: 0cm 0cm 0.0001pt 5.35pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">NIH</span></p>\n</td>\n<td style=\"width: 70.9pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"line-height: 11.7pt; margin: 0cm 0cm 0.0001pt 5.35pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">Low</span></p>\n</td>\n<td style=\"width: 49.35pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 13.55pt 0.0001pt 13.75pt; text-align: center; line-height: 11.7pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">29.5</span></p>\n</td>\n<td style=\"width: 104.05pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 5.2pt; line-height: 11.7pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">0/86 vs. 2/90</span></p>\n</td>\n<td style=\"width: 90.0pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 5.3pt; line-height: 11.7pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">N.E.</span></p>\n</td>\n<td style=\"width: 72.05pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 5.25pt; line-height: 11.7pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">100 vs. 98.7</span></p>\n</td>\n<td style=\"width: 68.1pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 4.75pt 0.0001pt 1.55pt; text-align: center; line-height: 11.7pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">100 vs. 95.5</span></p>\n</td>\n</tr>\n<tr style=\"height: 13.15pt;\">\n<td style=\"width: 46.65pt; border-top: none; border-left: solid #231F20 1.0pt; border-bottom: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n</td>\n<td style=\"width: 70.9pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0.05pt 0cm 0.0001pt 5.35pt; line-height: 12.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">Intermediate</span></p>\n</td>\n<td style=\"width: 49.35pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0.05pt 13.55pt 0.0001pt 13.75pt; text-align: center; line-height: 12.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">25.7</span></p>\n</td>\n<td style=\"width: 104.05pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0.05pt 0cm 0.0001pt 5.2pt; line-height: 12.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">4/75 vs. 6/78</span></p>\n</td>\n<td style=\"width: 90.0pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0.05pt 0cm 0.0001pt 5.3pt; line-height: 12.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">0.59 (0.17; 2.10)</span></p>\n</td>\n<td style=\"width: 72.05pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0.05pt 0cm 0.0001pt 5.25pt; line-height: 12.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">100 vs. 94.8</span></p>\n</td>\n<td style=\"width: 68.1pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0.05pt 4.75pt 0.0001pt 4.25pt; text-align: center; line-height: 12.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">97.8 vs. 89.5</span></p>\n</td>\n</tr>\n<tr style=\"height: 12.9pt;\">\n<td style=\"width: 46.65pt; border-top: none; border-left: solid #231F20 1.0pt; border-bottom: solid black 1.0pt; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n</td>\n<td style=\"width: 70.9pt; border-top: none; border-left: none; border-bottom: solid black 1.0pt; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0.05pt 0cm 0.0001pt 5.35pt; line-height: 11.9pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">High</span></p>\n</td>\n<td style=\"width: 49.35pt; border-top: none; border-left: none; border-bottom: solid black 1.0pt; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0.05pt 13.55pt 0.0001pt 13.75pt; text-align: center; line-height: 11.9pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">44.8</span></p>\n</td>\n<td style=\"width: 104.05pt; border-top: none; border-left: none; border-bottom: solid black 1.0pt; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0.05pt 0cm 0.0001pt 5.2pt; line-height: 11.9pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">21/140 vs. 51/127</span></p>\n</td>\n<td style=\"width: 90.0pt; border-top: none; border-left: none; border-bottom: solid black 1.0pt; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0.05pt 0cm 0.0001pt 5.3pt; line-height: 11.9pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">0.29 (0.18; 0.49)</span></p>\n</td>\n<td style=\"width: 72.05pt; border-top: none; border-left: none; border-bottom: solid black 1.0pt; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0.05pt 0cm 0.0001pt 5.25pt; line-height: 11.9pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">94.8 vs. 64.0</span></p>\n</td>\n<td style=\"width: 68.1pt; border-top: none; border-left: none; border-bottom: solid black 1.0pt; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0.05pt 4.75pt 0.0001pt 4.25pt; text-align: center; line-height: 11.9pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">80.7 vs. 46.6</span></p>\n</td>\n</tr>\n<tr style=\"height: 12.8pt;\">\n<td style=\"width: 46.65pt; border-top: none; border-left: solid #231F20 1.0pt; border-bottom: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"line-height: 11.8pt; margin: 0cm 0cm 0.0001pt 5.35pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">AFIP</span></p>\n</td>\n<td style=\"width: 70.9pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"line-height: 11.8pt; margin: 0cm 0cm 0.0001pt 5.35pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">Very Low</span></p>\n</td>\n<td style=\"width: 49.35pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 13.55pt 0.0001pt 13.75pt; text-align: center; line-height: 11.8pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">20.7</span></p>\n</td>\n<td style=\"width: 104.05pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 5.2pt; line-height: 11.8pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">0/52 vs. 2/63</span></p>\n</td>\n<td style=\"width: 90.0pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 5.3pt; line-height: 11.8pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">N.E.</span></p>\n</td>\n<td style=\"width: 72.05pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 5.25pt; line-height: 11.8pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">100 vs. 98.1</span></p>\n</td>\n<td style=\"width: 68.1pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 4.75pt 0.0001pt 1.5pt; text-align: center; line-height: 11.8pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">100 vs. 93.0</span></p>\n</td>\n</tr>\n<tr style=\"height: 13.1pt;\">\n<td style=\"width: 46.65pt; border-top: none; border-left: solid #231F20 1.0pt; border-bottom: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n</td>\n<td style=\"width: 70.9pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0.05pt 0cm 0.0001pt 5.35pt; line-height: 12.1pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">Low</span></p>\n</td>\n<td style=\"width: 49.35pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0.05pt 13.55pt 0.0001pt 13.75pt; text-align: center; line-height: 12.1pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">25.0</span></p>\n</td>\n<td style=\"width: 104.05pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0.05pt 0cm 0.0001pt 5.2pt; line-height: 12.1pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">2/70 vs. 0/69</span></p>\n</td>\n<td style=\"width: 90.0pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0.05pt 0cm 0.0001pt 5.3pt; line-height: 12.1pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">N.E.</span></p>\n</td>\n<td style=\"width: 72.05pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0.05pt 0cm 0.0001pt 5.25pt; line-height: 12.1pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">100 vs. 100</span></p>\n</td>\n<td style=\"width: 68.1pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0.05pt 0cm 0.0001pt 5.2pt; line-height: 12.1pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">97.8 vs. 100</span></p>\n</td>\n</tr>\n<tr style=\"height: 13.1pt;\">\n<td style=\"width: 46.65pt; border-top: none; border-left: solid #231F20 1.0pt; border-bottom: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n</td>\n<td style=\"width: 70.9pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"line-height: 12.15pt; margin: 0cm 0cm 0.0001pt 5.35pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">Moderate</span></p>\n</td>\n<td style=\"width: 49.35pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 13.55pt 0.0001pt 13.75pt; text-align: center; line-height: 12.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">24.6</span></p>\n</td>\n<td style=\"width: 104.05pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 5.2pt; line-height: 12.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">2/70 vs. 11/67</span></p>\n</td>\n<td style=\"width: 90.0pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 5.3pt; line-height: 12.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">0.16 (0.03; 0.70)</span></p>\n</td>\n<td style=\"width: 72.05pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 5.25pt; line-height: 12.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">97.9 vs. 90.8</span></p>\n</td>\n<td style=\"width: 68.1pt; border: none; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 4.75pt 0.0001pt 4.25pt; text-align: center; line-height: 12.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">97.9 vs. 73.3</span></p>\n</td>\n</tr>\n<tr style=\"height: 12.95pt;\">\n<td style=\"width: 46.65pt; border: solid #231F20 1.0pt; border-top: none; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n</td>\n<td style=\"width: 70.9pt; border-top: none; border-left: none; border-bottom: solid #231F20 1.0pt; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0.05pt 0cm 0.0001pt 5.35pt; line-height: 11.95pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">High</span></p>\n</td>\n<td style=\"width: 49.35pt; border-top: none; border-left: none; border-bottom: solid #231F20 1.0pt; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0.05pt 13.45pt 0.0001pt 13.9pt; text-align: center; line-height: 11.95pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">29.7</span></p>\n</td>\n<td style=\"width: 104.05pt; border-top: none; border-left: none; border-bottom: solid #231F20 1.0pt; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0.05pt 0cm 0.0001pt 5.2pt; line-height: 11.95pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">16/84 vs. 39/81</span></p>\n</td>\n<td style=\"width: 90.0pt; border-top: none; border-left: none; border-bottom: solid #231F20 1.0pt; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0.05pt 0cm 0.0001pt 5.3pt; line-height: 11.95pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">0.27 (0.15; 0.48)</span></p>\n</td>\n<td style=\"width: 72.05pt; border-top: none; border-left: none; border-bottom: solid #231F20 1.0pt; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0.05pt 0cm 0.0001pt 5.25pt; line-height: 11.95pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">98.7 vs. 56.1</span></p>\n</td>\n<td style=\"width: 68.1pt; border-top: none; border-left: none; border-bottom: solid #231F20 1.0pt; border-right: solid #231F20 1.0pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0.05pt 4.75pt 0.0001pt 4.25pt; text-align: center; line-height: 11.95pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">79.9 vs. 41.5</span></p>\n</td>\n</tr>\n</tbody>\n</table>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">* Full follow-up period; NE &#8211; Not estimable</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">A second multicentre, open label phase III study (SSG XVIII/AIO) compared 400 mg/day </span><span style=\"color: black;\">imatinib</span><span style=\"color: black;\"> 12 months treatment vs. 36 months treatment in patients after surgical resection of GIST and one of the following: tumour diameter &gt; 5 cm and mitotic count &gt; 5/50 high power fields (HPF); or tumour diameter &gt; 10 cm and any mitotic count or tumour of any size with mitotic count &gt; 10/50 HPF or tumours ruptured into the peritoneal cavity. There were a total of 397 patients consented and randomised to the study (199 patients on 12-month arm and 198 patients on 36-month arm), median age was 61 years (range 22 to 84 years). The median time of follow-up was 54 months (from date of randomisation to data cut-off), with a total of 83 months between the first patient randomised and the cut-off date.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">The primary endpoint of the study was recurrence-free survival (RFS), defined as the time from date of randomisation to the date of recurrence or death from any cause.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Thirty-six (36) months of </span><span style=\"color: black;\">imatinib</span><span style=\"color: black;\"> treatment significantly prolonged RFS compared to 12 months of </span><span style=\"color: black;\">imatinib</span><span style=\"color: black;\"> treatment (with overall Hazard Ratio (HR) = 0.46 [0.32, 0.65], p&lt;0.0001) (Table 8, Figure 1).</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">In addition, thirty-six (36) months of </span><span style=\"color: black;\">imatinib</span><span style=\"color: black;\"> treatment significantly prolonged overall survival (OS) compared to 12 months of </span><span style=\"color: black;\">imatinib</span><span style=\"color: black;\"> treatment (HR = 0.45 [0.22, 0.89], p=0.0187) (Table 8, Figure 2).</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Longer duration of the treatment (&gt; 36 months) may delay the onset of further recurrences; however the impact of this finding on the overall survival remains unknown.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">The total number of deaths were 25 for the 12-month treatment arm and 12 for the 36-month treatment arm.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Treatment with imatinib for 36 months was superior to treatment for 12 months in the ITT analysis, i.e. including the entire study population. In a planned subgroup analysis by mutation type, the HR for RFS for 36 months of treatment for patients with mutations of exon 11 was 0.35 [95% CI: 0.22, 0.56]. No conclusions can be drawn for other less common mutation subgroups due to the low number of observed events.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: black;\">Table 8&#160;&#160;&#160;&#160; 12-month and 36-month imatinib treatment (SSGXVIII/AIO Trial)</span></strong></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<table class=\"MsoNormalTable\" style=\"border-collapse: collapse; width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td style=\"width: 34.6154%; padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 6.1pt; line-height: 11.3pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: #231f20;\">RFS</span></strong></p>\n</td>\n<td style=\"width: 33.3333%; padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 47.25pt; line-height: 11.3pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: #231f20;\">%(CI)</span></strong></p>\n</td>\n<td style=\"width: 32.2115%; padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 41.75pt; line-height: 11.3pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: #231f20;\">%(CI)</span></strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 34.6154%; padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 47.15pt 0.0001pt 0cm; text-align: right; line-height: 11.55pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">12 months</span></p>\n</td>\n<td style=\"width: 33.3333%; padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 47.25pt; line-height: 11.55pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">93.7 (89.2-96.4)</span></p>\n</td>\n<td style=\"width: 32.2115%; padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 41.75pt; line-height: 11.55pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">95.9 (91.9-97.9)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 34.6154%; padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 47.15pt 0.0001pt 0cm; text-align: right; line-height: 11.65pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">24 months</span></p>\n</td>\n<td style=\"width: 33.3333%; padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 47.25pt; line-height: 11.65pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">75.4 (68.6-81.0)</span></p>\n</td>\n<td style=\"width: 32.2115%; padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 41.75pt; line-height: 11.65pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">90.7 (85.6-94.0)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 34.6154%; padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 47.15pt 0.0001pt 0cm; text-align: right; line-height: 11.65pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">36 months</span></p>\n</td>\n<td style=\"width: 33.3333%; padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 47.25pt; line-height: 11.65pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">60.1 (52.5-66.9)</span></p>\n</td>\n<td style=\"width: 32.2115%; padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 41.75pt; line-height: 11.65pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">86.6 (80.8-90.8)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 34.6154%; padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 47.15pt 0.0001pt 0cm; text-align: right; line-height: 11.65pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">48 months</span></p>\n</td>\n<td style=\"width: 33.3333%; padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 47.25pt; line-height: 11.65pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">52.3 (44.0-59.8)</span></p>\n</td>\n<td style=\"width: 32.2115%; padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 41.75pt; line-height: 11.65pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">78.3 (70.8-84.1)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 34.6154%; padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 47.15pt 0.0001pt 0cm; text-align: right; line-height: 11.7pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">60 months</span></p>\n</td>\n<td style=\"width: 33.3333%; padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 47.25pt; line-height: 11.7pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">47.9 (39.0-56.3)</span></p>\n</td>\n<td style=\"width: 32.2115%; padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 41.75pt; line-height: 11.7pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">65.6 (56.1-73.4)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 34.6154%; padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 6.1pt; line-height: 11.55pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: #231f20;\">Survival</span></strong></p>\n</td>\n<td style=\"width: 33.3333%; padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt;\">&#160;</span></p>\n</td>\n<td style=\"width: 32.2115%; padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt;\">&#160;</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 34.6154%; padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 47.15pt 0.0001pt 0cm; text-align: right; line-height: 11.65pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">36 months</span></p>\n</td>\n<td style=\"width: 33.3333%; padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 47.25pt; line-height: 11.65pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">94.0 (89.5-96.7)</span></p>\n</td>\n<td style=\"width: 32.2115%; padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 41.75pt; line-height: 11.65pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">96.3 (92.4-98.2)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 34.6154%; padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 47.15pt 0.0001pt 0cm; text-align: right; line-height: 11.65pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">48 months</span></p>\n</td>\n<td style=\"width: 33.3333%; padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 47.25pt; line-height: 11.65pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">87.9 (81.1-92.3)</span></p>\n</td>\n<td style=\"width: 32.2115%; padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 41.75pt; line-height: 11.65pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">95.6 (91.2-97.8)</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 34.6154%; border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid rgb(35, 31, 32); padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 47.15pt 0.0001pt 0cm; text-align: right; line-height: 11.7pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">60 months</span></p>\n</td>\n<td style=\"width: 33.3333%; border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid rgb(35, 31, 32); padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 47.25pt; line-height: 11.7pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">81.7 (73.0-87.8)</span></p>\n</td>\n<td style=\"width: 32.2115%; border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid rgb(35, 31, 32); padding: 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 41.75pt; line-height: 11.7pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: #231f20;\">92.0 (85.3-95.7)</span></p>\n</td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"line-height: normal; break-after: avoid; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: #231f20;\">Figure 1&#160;&#160;&#160;&#160;&#160; Kaplan-Meier estimates for primary recurrence-free survival endpoint (ITT &#160;&#160;&#160; population)</span></strong></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><img src=\"~/_entity/annotation/af8aaa81-f931-ee11-bdf4-000d3aaa0146\" /></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<table class=\"MsoNormalTable\" style=\"border-collapse: collapse;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td style=\"width: 83.75pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 2.1pt 0cm 0.0001pt 2.5pt; line-height: 10.6pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">At-risk : Events</span></p>\n</td>\n<td style=\"width: 425.0pt; padding: 0cm 0cm 0cm 0cm;\" colspan=\"11\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt;\">&#160;</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 83.75pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 3.8pt; line-height: 9.25pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">(1)&#160;&#160;&#160;&#160; 199:0&#160;&#160;&#160;&#160; 182:8</span></p>\n</td>\n<td style=\"width: 36.75pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 5.8pt; line-height: 9.25pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">177:12</span></p>\n</td>\n<td style=\"width: 35.45pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 5.1pt 0.0001pt; text-align: center; line-height: 9.25pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">163:25</span></p>\n</td>\n<td style=\"width: 35.45pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 6.15pt; line-height: 9.25pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">137:46</span></p>\n</td>\n<td style=\"width: 35.4pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 5.2pt 0.0001pt 5.15pt; text-align: center; line-height: 9.25pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">105:65</span></p>\n</td>\n<td style=\"width: 35.45pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 5.1pt 0.0001pt 1pt; text-align: center; line-height: 9.25pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">88:72</span></p>\n</td>\n<td style=\"width: 35.45pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 6.2pt; line-height: 9.25pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">61:77</span></p>\n</td>\n<td style=\"width: 32.65pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 4.9pt 0.0001pt 5.2pt; text-align: center; line-height: 9.25pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">49:81</span></p>\n</td>\n<td style=\"width: 93.15pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 0.15pt; text-align: center; line-height: 9.25pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">36:83&#160;&#160;&#160;&#160;&#160; 27:84&#160;&#160;&#160;&#160; 14:84</span></p>\n</td>\n<td style=\"width: 1.0cm; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 6.35pt; line-height: 9.25pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">10:84</span></p>\n</td>\n<td style=\"width: 27.95pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 6.1pt; line-height: 9.25pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">2:84</span></p>\n</td>\n<td style=\"width: 28.95pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 6.3pt; line-height: 9.25pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">0:84</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 83.75pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 3.8pt; line-height: 10.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">(2)&#160;&#160;&#160;&#160; 198:0&#160;&#160;&#160;&#160; 189:5</span></p>\n</td>\n<td style=\"width: 36.75pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 5.8pt; line-height: 10.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">184:8</span></p>\n</td>\n<td style=\"width: 35.45pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 5.1pt 0.0001pt; text-align: center; line-height: 10.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">181:11</span></p>\n</td>\n<td style=\"width: 35.45pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 6.15pt; line-height: 10.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">173:18</span></p>\n</td>\n<td style=\"width: 35.4pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 5.2pt 0.0001pt 5.15pt; text-align: center; line-height: 10.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">152:22</span></p>\n</td>\n<td style=\"width: 35.45pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 5.1pt 0.0001pt 5.25pt; text-align: center; line-height: 10.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">133:25</span></p>\n</td>\n<td style=\"width: 35.45pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 6.2pt; line-height: 10.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">102:29</span></p>\n</td>\n<td style=\"width: 32.65pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 4.9pt 0.0001pt 5.2pt; text-align: center; line-height: 10.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">82:35</span></p>\n</td>\n<td style=\"width: 93.15pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 0.15pt; text-align: center; line-height: 10.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">54:46&#160;&#160;&#160;&#160;&#160; 39:47&#160;&#160;&#160;&#160; 21:49</span></p>\n</td>\n<td style=\"width: 1.0cm; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 6.35pt; line-height: 10.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">8:50</span></p>\n</td>\n<td style=\"width: 27.95pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 6.1pt; line-height: 10.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">0:50</span></p>\n</td>\n<td style=\"width: 28.95pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt;\">&#160;</span></p>\n</td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"line-height: normal; break-after: avoid; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><strong><span style=\"color: #231f20;\">Figure 2&#160;&#160;&#160;&#160;&#160; Kaplan-Meier estimates for overall survival (ITT population)</span></strong></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\"><img src=\"~/_entity/annotation/891616fa-fd31-ee11-bdf4-000d3aaa0146\" /></span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<table class=\"MsoNormalTable\" style=\"border-collapse: collapse;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 3.0cm; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 2.1pt 0cm 0.0001pt -14.6pt; text-indent: 17.1pt; line-height: 10.65pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">At-risk : Events</span></p>\n</td>\n<td style=\"width: 15.0cm; padding: 0cm 0cm 0cm 0cm;\" colspan=\"11\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt;\">&#160;</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 3.0cm; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 3.8pt; line-height: 9.25pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">(1)&#160;&#160;&#160;&#160; 199:0&#160;&#160;&#160;&#160; 190:2</span></p>\n</td>\n<td style=\"width: 35.45pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 5.8pt; line-height: 9.25pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">188:2</span></p>\n</td>\n<td style=\"width: 35.45pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 5.1pt 0.0001pt; text-align: center; line-height: 9.25pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">183:6</span></p>\n</td>\n<td style=\"width: 35.45pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 6.15pt; line-height: 9.25pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">176:8</span></p>\n</td>\n<td style=\"width: 35.4pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 5.2pt 0.0001pt 5.15pt; text-align: center; line-height: 9.25pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">156:10</span></p>\n</td>\n<td style=\"width: 35.45pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 5.1pt 0.0001pt 1pt; text-align: right; line-height: 9.25pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">140:11</span></p>\n</td>\n<td style=\"width: 35.45pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 6.2pt; line-height: 9.25pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">105:14</span></p>\n</td>\n<td style=\"width: 32.65pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 4.9pt 0.0001pt 5.2pt; text-align: center; line-height: 9.25pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">87:18</span></p>\n</td>\n<td style=\"width: 93.15pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 0.15pt; text-align: center; line-height: 9.25pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">64:22&#160;&#160;&#160;&#160;&#160; 46:23&#160;&#160;&#160;&#160; 27:25</span></p>\n</td>\n<td style=\"width: 1.0cm; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 6.35pt; line-height: 9.25pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">20:25</span></p>\n</td>\n<td style=\"width: 27.95pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 6.1pt; line-height: 9.25pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">2:25</span></p>\n</td>\n<td style=\"width: 30.5pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 6.3pt; line-height: 9.25pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">0:25</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 3.0cm; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 3.8pt; line-height: 10.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">(2)&#160;&#160;&#160;&#160; 198:0&#160;&#160;&#160;&#160; 196:0</span></p>\n</td>\n<td style=\"width: 35.45pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 5.8pt; line-height: 10.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">192:0</span></p>\n</td>\n<td style=\"width: 35.45pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 5.1pt 0.0001pt; text-align: center; line-height: 10.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">187:4</span></p>\n</td>\n<td style=\"width: 35.45pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 6.15pt; line-height: 10.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">184:5</span></p>\n</td>\n<td style=\"width: 35.4pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 5.2pt 0.0001pt 5.15pt; line-height: 10.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">164:7</span></p>\n</td>\n<td style=\"width: 35.45pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 5.1pt 0.0001pt 5.25pt; line-height: 10.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">152:7</span></p>\n</td>\n<td style=\"width: 35.45pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 6.2pt; line-height: 10.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">119:8</span></p>\n</td>\n<td style=\"width: 32.65pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 4.9pt 0.0001pt 5.2pt; line-height: 10.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">100:8</span></p>\n</td>\n<td style=\"width: 93.15pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 0.15pt; text-align: center; line-height: 10.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">76:10&#160;&#160;&#160;&#160;&#160; 56:11&#160;&#160;&#160;&#160; 31:11</span></p>\n</td>\n<td style=\"width: 1.0cm; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 6.35pt; line-height: 10.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">13:12</span></p>\n</td>\n<td style=\"width: 27.95pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"margin: 0cm 0cm 0.0001pt 6.1pt; line-height: 10.15pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt; color: #231f20;\">0:12</span></p>\n</td>\n<td style=\"width: 30.5pt; padding: 0cm 0cm 0cm 0cm;\" valign=\"top\">\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 9.0pt;\">&#160;</span></p>\n</td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt; color: black;\">There are no controlled trials in paediatric patients with c-Kit positive GIST. Seventeen (17) patients with GIST (with or without Kit and PDGFR mutations) were reported in 7 publications. The age of these patients ranged from 8 to 18 years and imatinib was given in both adjuvant and metastatic settings at doses ranging from 300 to 800 mg daily. The majority of paediatric patients treated for GIST lacked data confirming c-kit or PDGFR mutations which may have led to mixed clinical outcomes.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u><span style=\"color: black;\">Clinical studies in DFSP</span></u></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt; color: black;\">One phase II, open label, multicentre clinical trial (study B2225) was conducted including 12 patients with DFSP treated with imatinib 800&#160;mg daily. The age of the DFSP patients ranged from 23 to 75 years; DFSP was metastatic, locally recurrent following initial resective surgery and not considered amenable to further resective surgery at the time of study entry. The primary evidence of </span><span style=\"font-size: 11.0pt;\">efficacy was based on objective response rates. Out of the 12 patients enrolled, 9 responded, one completely and 8 partially. Three of the partial responders were subsequently rendered disease free by surgery. The median duration of therapy in study B2225 was 6.2 months, with a maximum duration of 24.3 months. A further 6 DFSP patients treated with imatinib were reported in 5 published case reports, their ages ranging from 18 months to 49 years. The adult patients reported in the published literature were treated with either 400&#160;mg (4 cases) or 800&#160;mg (1 case) imatinib daily. Five (5) patients responded, 3 completely and 2 partially. The median duration of therapy in the published literature ranged between 4 weeks and more than 20 months. The translocation t(17:22)[(q22:q13)], or its gene product, was present in nearly all responders to imatinib treatment.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt; color: black;\">&#160;</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; text-align: left; font-size: 12pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt; color: black;\">There are no controlled trials in paediatric patients with DFSP. Five (5)</span><span style=\"font-size: 11.0pt; color: black;\">&#160;</span><span style=\"font-size: 11.0pt; color: black;\">patients with DFSP and PDGFR gene re-arrangements were reported in 3</span><span style=\"font-size: 11.0pt; color: black;\">&#160;</span><span style=\"font-size: 11.0pt; color: black;\">publications. The age of these patients ranged from newborn to 14</span><span style=\"font-size: 11.0pt; color: black;\">&#160;</span><span style=\"font-size: 11.0pt; color: black;\">years and imatinib was given at dose 50&#160;mg daily or doses ranging from 400 to 520</span><span style=\"font-size: 11.0pt; color: black;\">&#160;</span><span style=\"font-size: 11.0pt; color: black;\">mg/m<sup>2</sup> daily. All patients achieved partial and/or complete response.</span></p>"
                                                    }
                                                },
                                                {
                                                    "id": "7c2d755b-0932-ee11-bdf4-000d3aaa0146",
                                                    "title": "5.2 Pharmacokinetic properties",
                                                    "code": {
                                                        "coding": [
                                                            {
                                                                "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                                "code": "200000029827",
                                                                "display": "5.2 Pharmacokinetic properties"
                                                            }
                                                        ]
                                                    },
                                                    "text": {
                                                        "status": "generated",
                                                        "div": "<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Pharmacokinetics of imatinib</u></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">The pharmacokinetics of imatinib have been evaluated over a dosage range of 25 to 1,000&#160;mg. Plasma pharmacokinetic profiles were analysed on day 1 and on either day 7 or day 28, by which time plasma concentrations had reached steady state.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Absorption</u></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Mean absolute bioavailability for <span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">the capsule formulation </span> is 98%. There was high between-patient variability in plasma imatinib AUC levels after an oral dose. When given with a high-fat meal, the rate of absorption of imatinib was minimally reduced (11% decrease in C<sub>max</sub> and prolongation of t<sub>max</sub> by 1.5&#160;h), with a small reduction in AUC (7.4%) compared to fasting conditions. The effect of prior gastrointestinal surgery on drug absorption has not been investigated.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Distribution</u></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">At clinically relevant concentrations of imatinib, binding to plasma proteins was approximately 95% on the basis of <em>in vitro </em>experiments, mostly to albumin and alpha-acid-glycoprotein, with little binding to lipoprotein.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Biotransformation</u></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">The main circulating metabolite in humans is the N‑demethylated piperazine derivative, which shows similar <em>in vitro </em>potency to the parent. The plasma AUC for this metabolite was found to be only 16% of the AUC for imatinib. The plasma protein binding of the N‑demethylated metabolite is similar to that of the parent compound.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Imatinib and the N-demethyl metabolite together accounted for about 65% of the circulating radioactivity (AUC<sub>(0‑48h)</sub>). The remaining circulating radioactivity consisted of a number of minor metabolites.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">The <em>in vitro </em>results showed that CYP3A4 was the major human P450 enzyme catalysing the biotransformation of imatinib. Of a panel of potential comedications (acetaminophen, aciclovir, allopurinol, amphotericin, cytarabine, erythromycin, fluconazole, hydroxyurea, norfloxacin, penicillin&#160;V) only erythromycin (IC<sub>50</sub> 50&#160;&#956;M) and fluconazole (IC<sub>50</sub> 118&#160;&#956;M) showed inhibition of imatinib metabolism which could have clinical relevance.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Imatinib was shown <em>in vitro </em>to be a competitive inhibitor of marker substrates for CYP2C9, CYP2D6 and CYP3A4/5. K<sub>i</sub> values in human liver microsomes were 27, 7.5 and 7.9&#160;&#181;mol/l, respectively. Maximal plasma concentrations of imatinib in patients are 2‑4&#160;&#181;mol/l, consequently an inhibition of CYP2D6 and/or CYP3A4/5‑mediated metabolism of co‑administered drugs is possible. Imatinib did not interfere with the biotransformation of 5‑fluorouracil, but it inhibited paclitaxel metabolism as a result of competitive inhibition of CYP2C8 (K<sub>i&#160;</sub>=&#160;34.7&#160;&#956;M). This K<sub>i</sub> value is far higher than the expected plasma levels of imatinib in patients; consequently no interaction is expected upon co‑administration of either 5‑fluorouracil or paclitaxel and imatinib.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Elimination</u></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Based on the recovery of compound(s) after an oral <sup>14</sup>C‑labelled dose of imatinib, approximately 81% of the dose was recovered within 7 days in faeces (68% of dose) and urine (13% of dose). Unchanged imatinib accounted for 25% of the dose (5% urine, 20% faeces), the remainder being metabolites.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Plasma pharmacokinetics</u></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Following oral administration in healthy volunteers, the t<sub>&#189;</sub> was approximately 18&#160;h, suggesting that once‑daily dosing is appropriate. The increase in mean AUC with increasing dose was linear and dose proportional in the range of 25‑1,000&#160;mg imatinib after oral administration. There was no change in the kinetics of imatinib on repeated dosing, and accumulation was 1.5‑2.5‑fold at steady state when dosed once daily.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Pharmacokinetics in GIST patients</u></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">In patients with GIST steady-state exposure was 1.5-fold higher than that observed for CML patients for the same dosage (400 mg daily). Based on preliminary population pharmacokinetic analysis in GIST patients, there were three variables (albumin, WBC and bilirubin) found to have a statistically significant relationship with imatinib pharmacokinetics. Decreased values of albumin caused a reduced clearance (CL/f); and higher levels of WBC led to a reduction of CL/f. However, these associations are not sufficiently pronounced to warrant dose adjustment. In this patient population, the presence of hepatic metastases could potentially lead to hepatic insufficiency and reduced metabolism.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Population pharmacokinetics</u></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Based on population pharmacokinetic analysis in CML patients, there was a small effect of age on the volume of distribution (12% increase in patients&#160;&gt;&#160;65 years old). This change is not thought to be clinically significant. The effect of bodyweight on the clearance of imatinib is such that for a patient weighing 50&#160;kg the mean clearance is expected to be 8.5&#160;l/h, while for a patient weighing 100&#160;kg the clearance will rise to 11.8&#160;l/h. These changes are not considered sufficient to warrant dose adjustment based on kg bodyweight. There is no effect of gender on the kinetics of imatinib.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Pharmacokinetics in paediatric population</u></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">As in adult patients, imatinib was rapidly absorbed after oral administration in paediatric patients in both phase I and phase II studies. Dosing in children at 260 and 340&#160;mg/m<sup>2</sup>/day achieved the same exposure, respectively, as doses of 400&#160;mg and 600&#160;mg in adult patients. The comparison of AUC<sub>(0‑24) </sub>on day 8 and day 1 at the 340&#160;mg/m<sup>2</sup>/day dose level revealed a 1.7‑fold drug accumulation after repeated once-daily dosing.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Based on pooled population pharmacokinetic analysis in paediatric patients with haematological disorders (CML, Ph+ALL, or other haematological disorders treated with imatinib), clearance of imatinib increases with increasing body surface area (BSA). After correcting for the BSA effect, other demographics such as age, body weight and body mass index did not have clinically significant effects on the exposure of imatinib. The analysis confirmed that exposure of imatinib in paediatric patients receiving 260&#160;mg/m<sup>2</sup> once daily (not exceeding 400&#160;mg once daily) or 340&#160;mg/m<sup>2</sup> once daily (not exceeding 600&#160;mg once daily) were similar to those in adult patients who received imatinib 400&#160;mg or 600&#160;mg once daily.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Organ function impairment</u></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Imatinib and its metabolites are not excreted via the kidney to a significant extent. Patients with mild and moderate impairment of renal function appear to have a higher plasma exposure than patients with normal renal function. The increase is approximately 1.5 to 2‑fold, corresponding to a 1.5‑fold elevation of plasma AGP, to which imatinib binds strongly. The free drug clearance of imatinib is probably similar between patients with renal impairment and those with normal renal function, since renal excretion represents only a minor elimination pathway for imatinib (see sections 4.2 and 4.4).</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Although the results of pharmacokinetic analysis showed that there is considerable inter-subject variation, the mean exposure to imatinib did not increase in patients with varying degrees of liver dysfunction as compared to patients with normal liver function (see sections 4.2, 4.4 and 4.8).</p>"
                                                    }
                                                },
                                                {
                                                    "id": "972d755b-0932-ee11-bdf4-000d3aaa0146",
                                                    "title": "5.3 Preclinical safety data",
                                                    "code": {
                                                        "coding": [
                                                            {
                                                                "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                                "code": "200000029834",
                                                                "display": "5.3 Preclinical safety data"
                                                            }
                                                        ]
                                                    },
                                                    "text": {
                                                        "status": "generated",
                                                        "div": "<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">The preclinical safety profile of imatinib was assessed in rats, dogs, monkeys and rabbits.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Multiple dose toxicity studies revealed mild to moderate haematological changes in rats, dogs and monkeys, accompanied by bone marrow changes in rats and dogs.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">The liver was a target organ in rats and dogs. Mild to moderate increases in transaminases and slight decreases in cholesterol, triglycerides, total protein and albumin levels were observed in both species. No histopathological changes were seen in rat liver. Severe liver toxicity was observed in dogs treated for 2 weeks, with elevated liver enzymes, hepatocellular necrosis, bile duct necrosis, and bile duct hyperplasia.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Renal toxicity was observed in monkeys treated for 2 weeks, with focal mineralisation and dilation of the renal tubules and tubular nephrosis. Increased blood urea nitrogen (BUN) and creatinine were observed in several of these animals. In rats, hyperplasia of the transitional epithelium in the renal papilla and in the urinary bladder was observed at doses&#160;&#8805;&#160;6&#160;mg/kg in the 13‑week study, without changes in serum or urinary parameters. An increased rate of opportunistic infections was observed with chronic imatinib treatment.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">In a 39‑week monkey study, no NOAEL (no observed adverse effect level) was established at the lowest dose of 15&#160;mg/kg, approximately one-third the maximum human dose of 800&#160;mg based on body surface. Treatment resulted in worsening of normally suppressed malarial infections in these animals.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Imatinib was not considered genotoxic when tested in an <em>in vitro </em>bacterial cell assay (Ames test), an <em>in vitro </em>mammalian cell assay (mouse lymphoma) and an <em>in vivo </em>rat micronucleus test. Positive genotoxic effects were obtained for imatinib in an <em>in vitro </em>mammalian cell assay (Chinese hamster ovary) for clastogenicity (chromosome aberration) in the presence of metabolic activation. Two intermediates of the manufacturing process, which are also present in the final product, are positive for mutagenesis in the Ames assay. One of these intermediates was also positive in the mouse lymphoma assay.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">In a study of fertility, in male rats dosed for 70 days prior to mating, testicular and epididymal weights and percent motile sperm were decreased at 60&#160;mg/kg, approximately equal to the maximum clinical dose of 800&#160;mg/day, based on body surface area. This was not seen at doses&#160;&#8804;&#160;20&#160;mg/kg. A slight to moderate reduction in spermatogenesis was also observed in the dog at oral doses&#160;&#8805;&#160;30&#160;mg/kg. When female rats were dosed 14 days prior to mating and through to gestational day 6, there was no effect on mating or on number of pregnant females. At a dose of 60&#160;mg/kg, female rats had significant post‑implantation foetal loss and a reduced number of live foetuses. This was not seen at doses&#160;&#8804;&#160;20&#160;mg/kg.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">In an oral pre- and postnatal development study in rats, red vaginal discharge was noted in the 45&#160;mg/kg/day group on either day 14 or day 15 of gestation. At the same dose, the number of stillborn pups as well as those dying between postpartum days 0 and 4 was increased. In the F<sub>1</sub> offspring, at the same dose level, mean body weights were reduced from birth until terminal sacrifice and the number of litters achieving criterion for preputial separation was slightly decreased. F<sub>1</sub> fertility was not affected, while an increased number of resorptions and a decreased number of viable foetuses was noted at 45&#160;mg/kg/day. The no observed effect level (NOEL) for both the maternal animals and the F<sub>1</sub> generation was 15&#160;mg/kg/day (one quarter of the maximum human dose of 800&#160;mg).</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Imatinib was teratogenic in rats when administered during organogenesis at doses&#160;&#8805;&#160;100&#160;mg/kg, approximately equal to the maximum clinical dose of 800&#160;mg/day, based on body surface area. Teratogenic effects included exencephaly or encephalocele, absent/reduced frontal and absent parietal bones. These effects were not seen at doses&#160;&#8804;&#160;30&#160;mg/kg.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">No new target organs were identified in the rat juvenile development toxicology study (day&#160;10 to 70 postpartum) with respect to the known target organs in adult rats. In the juvenile toxicology study, effects upon growth, delay in vaginal opening and preputial separation were observed at approximately 0.3 to 2&#160;times the average paediatric exposure at the highest recommended dose of 340&#160;mg/m<sup>2</sup>. In addition, mortality was observed in juvenile animals (around weaning phase) at approximately 2&#160;times the average paediatric exposure at the highest recommended dose of 340&#160;mg/m<sup>2</sup>.</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">In the 2‑year rat carcinogenicity study administration of imatinib at 15, 30 and 60&#160;mg/kg/day resulted in a statistically significant reduction in the longevity of males at 60&#160;mg/kg/day and females at &#8805;30&#160;mg/kg/day. Histopathological examination of decedents revealed cardiomyopathy (both sexes), chronic progressive nephropathy (females) and preputial gland papilloma as principal causes of death or reasons for sacrifice. Target organs for neoplastic changes were the kidneys, urinary bladder, urethra, preputial and clitoral gland, small intestine, parathyroid glands, adrenal glands and non‑glandular stomach.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Papilloma/carcinoma of the preputial/clitoral gland were noted from 30&#160;mg/kg/day onwards, representing approximately 0.5 or 0.3 times the human daily exposure (based on AUC) at 400&#160;mg/day or 800&#160;mg/day, respectively, and 0.4 times the daily exposure in children (based on AUC) at 340&#160;mg/m<sup>2</sup>/day. The no observed effect level (NOEL) was 15&#160;mg/kg/day. The renal adenoma/carcinoma, the urinary bladder and urethra papilloma, the small intestine adenocarcinomas, the parathyroid glands adenomas, the benign and malignant medullary tumours of the adrenal glands and the non‑glandular stomach papillomas/carcinomas were noted at 60&#160;mg/kg/day, representing approximately 1.7 or 1 times the human daily exposure (based on AUC) at 400&#160;mg/day or 800&#160;mg/day, respectively, and 1.2 times the daily exposure in children (based on AUC) at 340&#160;mg/m<sup>2</sup>/day. The no observed effect level (NOEL) was 30&#160;mg/kg/day.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">The mechanism and relevance of these findings in the rat carcinogenicity study for humans are not yet clarified.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Non‑neoplastic lesions not identified in earlier preclinical studies were the cardiovascular system, pancreas, endocrine organs and teeth. The most important changes included cardiac hypertrophy and dilatation, leading to signs of cardiac insufficiency in some animals.</p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">The active substance imatinib demonstrates an environmental risk for sediment organisms.</span></p>"
                                                    }
                                                }
                                            ]
                                        },
                                        {
                                            "id": "992d755b-0932-ee11-bdf4-000d3aaa0146",
                                            "title": "6. PHARMACEUTICAL PARTICULARS",
                                            "code": {
                                                "coding": [
                                                    {
                                                        "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                        "code": "200000029836",
                                                        "display": "6. PHARMACEUTICAL PARTICULARS"
                                                    }
                                                ]
                                            },
                                            "text": {
                                                "status": "generated"
                                            },
                                            "section": [
                                                {
                                                    "id": "9a2d755b-0932-ee11-bdf4-000d3aaa0146",
                                                    "title": "6.1 List of excipients",
                                                    "code": {
                                                        "coding": [
                                                            {
                                                                "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                                "code": "200000029837",
                                                                "display": "6.1 List of excipients"
                                                            }
                                                        ]
                                                    },
                                                    "text": {
                                                        "status": "generated",
                                                        "div": "<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u><span style=\"color: black;\">Capsule content</span></u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Mannitol</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Crospovidone</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Magnesium stearate</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Silica colloidal, anhydrous</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u><span style=\"color: black;\">Capsule shell</span></u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Gelatin</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Titanium dioxide (E171)</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Iron oxide, yellow (E172)</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Iron oxide, red (E172)</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u><span style=\"color: black;\">Printing ink</span></u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Shellac</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Iron oxide black (E172)</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Propylene glycol</p>"
                                                    }
                                                },
                                                {
                                                    "id": "9e2d755b-0932-ee11-bdf4-000d3aaa0146",
                                                    "title": "6.2 Incompatibilities",
                                                    "code": {
                                                        "coding": [
                                                            {
                                                                "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                                "code": "200000029838",
                                                                "display": "6.2 Incompatibilities"
                                                            }
                                                        ]
                                                    },
                                                    "text": {
                                                        "status": "generated",
                                                        "div": "<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Not applicable.</p>"
                                                    }
                                                },
                                                {
                                                    "id": "9f2d755b-0932-ee11-bdf4-000d3aaa0146",
                                                    "title": "6.3 Shelf life",
                                                    "code": {
                                                        "coding": [
                                                            {
                                                                "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                                "code": "200000029839",
                                                                "display": "6.3 Shelf life"
                                                            }
                                                        ]
                                                    },
                                                    "text": {
                                                        "status": "generated",
                                                        "div": "<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">2 years</p>"
                                                    }
                                                },
                                                {
                                                    "id": "a02d755b-0932-ee11-bdf4-000d3aaa0146",
                                                    "title": "6.4 Special precautions for storage",
                                                    "code": {
                                                        "coding": [
                                                            {
                                                                "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                                "code": "200000029840",
                                                                "display": "6.4 Special precautions for storage"
                                                            }
                                                        ]
                                                    },
                                                    "text": {
                                                        "status": "generated",
                                                        "div": "<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">This medicinal product does not require any special storage conditions.</p>"
                                                    }
                                                },
                                                {
                                                    "id": "a52d755b-0932-ee11-bdf4-000d3aaa0146",
                                                    "title": "6.5 Nature and contents of container",
                                                    "code": {
                                                        "coding": [
                                                            {
                                                                "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                                "code": "200000029841",
                                                                "display": "6.5 Nature and contents of container"
                                                            }
                                                        ]
                                                    },
                                                    "text": {
                                                        "status": "generated",
                                                        "div": "<p style=\"margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">PVC/PE/PVdC/PE/PVC//Al blisters</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">OPA/Al/PVC//Al blisters</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Imatinib Teva 100&#160;mg hard capsules</u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Pack sizes of 60 or 120, hard capsules in blisters.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Pack sizes of 20x1, 60x1, 120x1 or 180x1 hard capsules in perforated unit dose blisters.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><u>Imatinib Teva 400&#160;mg hard capsules</u></p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Pack sizes of 30 or 90 hard capsules in blisters.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Pack sizes of 30x1 or 90x1 hard capsules in perforated unit dose blisters.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Not all pack sizes may be marketed.</p>"
                                                    }
                                                },
                                                {
                                                    "id": "a82d755b-0932-ee11-bdf4-000d3aaa0146",
                                                    "title": "6.6 Special precautions for disposal",
                                                    "code": {
                                                        "coding": [
                                                            {
                                                                "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                                "code": "200000029842",
                                                                "display": "6.6 Special precautions for disposal"
                                                            }
                                                        ]
                                                    },
                                                    "text": {
                                                        "status": "generated",
                                                        "div": "<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"color: black;\">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</span></p>"
                                                    }
                                                }
                                            ]
                                        },
                                        {
                                            "id": "aa2d755b-0932-ee11-bdf4-000d3aaa0146",
                                            "title": "7. MARKETING AUTHORISATION HOLDER",
                                            "code": {
                                                "coding": [
                                                    {
                                                        "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                        "code": "200000029844",
                                                        "display": "7. MARKETING AUTHORISATION HOLDER"
                                                    }
                                                ]
                                            },
                                            "text": {
                                                "status": "generated",
                                                "div": "<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Teva B.V.</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Swensweg 5</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">2031 GA Haarlem</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">The Netherlands</p>"
                                            }
                                        },
                                        {
                                            "id": "ab2d755b-0932-ee11-bdf4-000d3aaa0146",
                                            "title": "8. MARKETING AUTHORISATION NUMBER(S)",
                                            "code": {
                                                "coding": [
                                                    {
                                                        "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                        "code": "200000029845",
                                                        "display": "8. MARKETING AUTHORISATION NUMBER(S)"
                                                    }
                                                ]
                                            },
                                            "text": {
                                                "status": "generated",
                                                "div": "<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">EU/1/12/808/021-040</p>"
                                            }
                                        },
                                        {
                                            "id": "ac2d755b-0932-ee11-bdf4-000d3aaa0146",
                                            "title": "9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION",
                                            "code": {
                                                "coding": [
                                                    {
                                                        "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                        "code": "200000029846",
                                                        "display": "9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION"
                                                    }
                                                ]
                                            },
                                            "text": {
                                                "status": "generated",
                                                "div": "<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Date of first authorisation: 08 January 2013</p>\n<p style=\"line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;\">Date of latest renewal: 18 September 2017</p>"
                                            }
                                        },
                                        {
                                            "id": "ad2d755b-0932-ee11-bdf4-000d3aaa0146",
                                            "title": "10. DATE OF REVISION OF THE TEXT",
                                            "code": {
                                                "coding": [
                                                    {
                                                        "system": "https://spor.ema.europa.eu/v1/lists/200000029659/terms/",
                                                        "code": "200000029847",
                                                        "display": "10. DATE OF REVISION OF THE TEXT"
                                                    }
                                                ]
                                            },
                                            "text": {
                                                "status": "generated",
                                                "div": "<p>&#160;</p>\n<p style=\"margin: 0cm -0.1pt 0.0001pt 0cm; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;\">Detailed information on this medicinal product is available on the website of the European Medicines Agency <a style=\"color: blue; text-decoration: underline;\" href=\"http://www.ema.europa.eu\">http://www.ema.europa.eu</a></p>"
                                            }
                                        }
                                    ]
                                }
                            ]
                        }
                    }
                ]
            },
            "search": {
                "mode": "match"
            }
        }
    ]
}